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1 Introduction   
1.1 General introduction 
1.1.1 Epidemiology and risk factors 
Lung cancer is characterized by the unlimited growth of cells of epithelial background in the 
lung and manifests with shortness of breath, hoarseness, cough and blood in sputum. Lung 
cancer is currently the leading cause of cancer deaths worldwide in both, men and women, 
and it accounts for over 30% of all deaths in both genders. Lung cancer is much more 
frequent than both prostate and breast cancer (Figure 1) and is among the 10 most common 
cancers. This is remarkable, since the number of estimated new cases for prostate and breast 
cancer together (470,930 new cases) is more than double the number of new lung cancer cases 
(228,190 cases, both genders combined). The incidence of lung cancer is especially elevated 
in North America, Europe and China. Overall, there is an aggregated (e.g. also non-smoker’s) 
probability of 7.77% for men and 6.35% for women of developing lung cancer in their 
lifetimes.  
The prognosis for lung cancer is poor, with an overall five-year survival rate of 15% at 
diagnosis (all stages combined). The survival rates according to the different lung cancer 
stages are summarized in Table 1.  
 
Figure 1 Estimated deaths of the 10 leading cancer types in 2013  (Siegel et al., 2013). 
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Notably, the five-year survival rate dramatically decreases to less than 5% as soon as invasive 
or metastatic processes are involved (from stage IIIB). 
Up from stage IIIB, the one-year survival rate is just 10%. When it is taken into account, that 
56% of all lung cancers are already stage III or more at the point of diagnosis, the highest 
fatality of lung cancer within all cancer diseases can be explained. Furthermore, 65-80% of 
patients present with already unresectable disease due to the advanced stage (Ferlay et al., 
2010; Malvezzi et al., 2012; Siegel et al., 2013; Siegel et al., 2011). 
 
 
 
 
 
 
By far, the greatest risk factor for lung cancer is tobacco use. Between 80% and 90% of all 
lung cancers worldwide are attributable to smoking, with a 20-fold increased risk of lung 
cancer in smokers compared to non-smokers. Interestingly, the increased risk of developing 
lung cancer is more dependent on the length of smoking history compared to smoking a 
greater amount of cigarettes. Moreover, these trends closely follow the rates of tobacco use of 
men and women over the years, and recent data show that the rates of lung cancer incidence 
are finally expected to decrease for both men and women as smoking demographics have 
changed. 
Nevertheless, this leaves a large number of lung cancer victims who have never smoked, and 
lung cancer deaths are the seventh leading cause of cancer mortality among individuals who 
have never smoked. 
A second risk factor is second-hand smoke, often referred to as environmental tobacco smoke 
(ETS), which is estimated to cause approximately 3,000 cases of lung cancer deaths each 
year. Studies reveal that spousal smoking increases the lung cancer risk of the non-smoking 
spouse by 30% and is dependent on duration and level of exposure. Similar increased risks are 
found in non-smokers exposed to ETS at work.  
Stage 5-year-survival rate 
I 60-80% 
II 25-50% 
IIIA 10-30% 
IIIB < 5% 
IV < 5% 
 
Table 1 Overall 5-year-survival in relation to the stage 
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In addition to smoking, there are several occupational exposure hazards that have been 
identified as risk factors for lung cancer, including chronic exposure to cooking fumes, 
ionizing radiation generated during CT scans, radon gas and asbestos, with heavy exposure to 
asbestos doubling the risk (Alberg and Samet, 2003; Sun et al., 2007; Taylor et al., 2007; 
Thun et al., 2008; Truong et al., 2010; Veglia et al., 2007). 
A more considerable contributor to lung cancer risk is pre-existing lung diseases, such as 
chronic obstructive pulmonary disease (COPD), asthma, pneumonia and tuberculosis. The 
most likely explanation for the increased lung cancer risk is the underlying inflammatory 
effect from these diseases, including the recruitment and activation of inflammatory cells that 
are accompanied by the expression of pro-inflammatory cytokines and chemokines, as well as 
the establishment of chemotactic gradients. Moreover, inflammation further initiates and 
promotes processes such as anti-apoptotic signaling, increased angiogenesis and increased 
generation of genetic mutations (Fitzpatrick, 2001; Kundu and Surh, 2008; McCarthy et al., 
2012; Zhang et al., 2000). 
Finally, genome-wide association studies have also identified several chromosome regions 
that suggest an inherited genetic susceptibility to lung cancer. The 5p15.33 locus, as well as 
the telomerase gene TERT (telomerase reverse transcriptase), was confirmed as being 
significantly correlated with lung cancer risk. TERT is critical for telomere replication and 
stabilization by controlling telomere length. Two additional loci, 6p21 and 6q23-25, could be 
related to increased lung cancer risk, although the direct involvement remains unclear (Gao et 
al., 2009; Schwartz and Ruckdeschel, 2006; Wang et al., 2009). 
1.1.2 Pathogenesis 
Lung carcinogenesis is influenced by a variety of environmental factors such as tobacco 
smoke, radiation and pre-existing inflammation that interact and may work synergistically 
with non-environmental factors, including genetic susceptibility, genetically determined 
variation in carcinogen metabolism and/or variability in DNA repair capacity (Caporaso et al., 
1991; Wei and Spitz, 1997). The initial step of carcinogenesis in lung cancer is DNA-damage 
in the epithelial layers of the bronchi, bronchioli and alveoli, most likely induced by 
carcinogens such as benzo[a]pyrene, a classic DNA damaging carcinogen abundantly found 
in tobacco smoke and the environment as a result of fuel combustion (Phillips, 1983). The 
metabolic processes in the human body itself generate highly toxic, electrophilic and free 
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radical reactive intermediates that form DNA adducts through covalent binding or oxidation 
(Gelboin, 1980; MacLeod and Tang, 1985). In tobacco smoke alone, over 55 pro-carcinogens 
and ultimate carcinogens can be found. The human organism is capable of repairing damaged 
DNA through various pathways, such as the nucleotide excision repair pathway (Sancar, 
1995). When the homeostasis of DNA damage and DNA repair becomes unstable and the 
level of DNA damage exceeds repair capabilities, genetic and epigenetic changes of the DNA 
remain permanent via mutations, loss of heterozygosity or promoter methylation (Wei et al., 
2000). 
Chronic changes on the DNA level can result in global transcriptome changes with 
deregulated pathways involved in proliferation and apoptosis. Epithelial cells can gain 
unlimited proliferative capacities and resistance to apoptosis and anoikis. These changes can 
persist over the long term and eventually lead to premalignant changes, including dysplasia 
and clonal patches (Mao et al., 1997; Spira et al., 2004). Premalignant patches contain clones 
and subclones (socalled insets), that can carry different mutations. Additionally, DNA damage 
or involvement of the tumor microenvironment can result in in situ cancer and further 
invasion to an advanced cancer with distant metastasis. Many molecular changes in the 
earliest stage of cancer also occur in advanced disease (Bianchi et al., 2004; Sato et al., 2007; 
Zudaire et al., 2008). 
Lung cancers differ in their localization within the lung, depending on the association with 
smoking: primary cancers related to smoking most often develop in the central airway 
(squamous cell carcinoma and small-cell lung cancer; see classification in 1.1.3), while 
cancers unrelated to smoking develop in the peripheral airways (adenocarcinoma) (Mao et al., 
1997; Wistuba et al., 2000). Moreover, lung cancers have strikingly different molecular 
profiles in smoking patients versus patients without a smoking history. 
Table 2 summarizes the most common DNA changes detected in lung cancer tissue from 
patients with different lung cancer subtypes. Genetic changes can be divided into two 
subtypes: either a mutation or amplification leads to higher activity of an oncogene, e.g. KRas 
or EGFR (epithelial growth factor receptor), or a tumor suppressor gene is suppressed or its 
tumor protecting function abolished, e.g. p53 (tumor protein 53).  
The most common mutation (accounting for approximately 70%), in SCLC (small-cell lung 
cancer) and NSCLC (non-small cell lung cancer) is the mutation of the tumor suppressor gene 
p53. The second-most abundant mutation (90%) in adenocarcinomas of the lung is the 
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activating GT transversion affecting exon12 in p53. KRas-mutations in adenocarcinomas 
are smoking-related and they generally mark a poor prognosis (Riely et al., 2008; Sun et al., 
2007; Westra, 2000). 
Abnormality Non-Small-Cell Lung Cancer 
(NSCLC) 
Small-Cell Lung 
Cancer 
(SCLC) 
 
Squamous-Cell 
Carcinoma 
Adenocarcinoma  
KRAS mutation Very rare 10-30% Very rare 
BRAF mutation 3% 2% Very rare 
EGFR    
    Kinase Domain mutation Very rare 10-40% Very rare 
    Amplification 30% 15% Very rare 
    Variant III mutation 5% Very rare Very rare 
HER2    
    Kinase Domain mutation Very rare 4% Very rare 
    Amplification 2% 6% Not known 
ALK fusion Very rare 7% Not known 
MET    
    Mutation 12% 14% 13% 
    Amplification 21% 20% Not known 
TITF-1 amplification 15% 15% Very rare 
p53 mutation 60 to 70% 50 to 70% 75% 
LKB1 mutation 19% 34% Very rare 
PIK3CA    
    Mutation 2% 2% Very rare 
    Amplification 33% 6% 4% 
 
Table 2 Summary of genetic abnormalities specific in lung cancer, adapted from (Herbst et al., 2008). 
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HER, human epidermal growth 
factor receptor 2; LKB1, liver kinase B1; MET, hepatocyte growth factor receptor; PIK3, Phosphatidylinositide 
3-kinases; TTF, thyroid transcription factor. 
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Also notable is the kinase domain mutation of the EGFR, which is detected in 10%–40% of 
all adenocarcinomas. EGFR regulates important tumorigenic processes, including 
proliferation, apoptosis, angiogenesis, and invasion. Among the mutations of the kinase 
domain, over 80% are involved in frame deletions in exon19. In contrast to the Kras 
mutations, EGFR mutations in adenocarcinomas have been identified in non-smokers and are 
associated with an improved prognosis (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004).  
Amplification (increased gene copy numbers or polysomy) of EGFR is the second-most 
frequent abnormality in squamous cell carcinoma (30%), and in this NSCLC subtype, it is 
related to smoking and associated with a poor prognosis (Hirsch et al., 2008; Tsao et al., 
2005). 
Further progression of lung tumors is still partially dependent on these initially occurring 
mutations, although the tumor microenvironment with non-neoplastic stromal cells might play 
a more important role in advanced stages of lung cancer and the metastatic spread of the 
primary tumor. In particular, the molecular mechanisms that initiate intravasation of tumor 
cells, circulation and the sub sequent extravasation at distant sites are incompletely 
understood and require further investigation. 
1.1.3 Classification 
Lung cancer is divided into two main groups based on histological features: small-cell lung 
cancer (SCLC) and non-small-cell lung cancer (NSCLC). NSCLC is further divided into 
squamous cell carcinoma, adenocarcinoma and large-cell carcinoma. Table 3 provides an 
overview and direct comparison of different lung cancer subtypes.  
Notably, adenocarcinoma is represented by distinct histological subtypes, which show 
significant differences in prognosis and treatment options, although most lung 
adenocarcinomas exhibit combinations of morphologic patterns. Further classification is 
based on invasiveness and ability to secrete mucins and include bronchoalveolar carcinoma 
(BAC; carcinoma in situ), minimally invasive adenocarcinoma (MIA) and invasive 
adenocarcinoma (IA) with lepidic, acinary, pappillary, micropappillary or solid growth 
(Finberg et al., 2007; Motoi et al., 2008; Travis et al., 2011). The applied therapy is selected 
based on the correct differential diagnosis of the lung cancer subtype and is therefore crucial 
for the patient’s prognosis. 
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Small cell lung 
cancer (SCLC) 
Non-small cell lung cancer (NSCLC) 
Adenocarcinoma Squamous cell 
carcinoma 
Large cell 
carcinoma 
Histology 
 
Incidence 
[%] 
 
Male vs. 
female 
 
Location 
 
 
 
 
Marker NSE, proGRP TTF-1, Napsin A, 
CK7, CEA 
P63, CK5/6, Sox2. 
CYFRA 21-1 
CEA 
Smoking 
relation 
    
Growth Very rapid Intermediate Relatively slow Rapid 
Metastatic 
tendency 
Very early; to 
mediastinum or 
distaly 
Intermediate Later, then 
primarly to hilar 
nodes 
Early 
Resectability almost none poor fair poor 
 
Table 3 Characteristics of histological lung cancer subtypes. NSE, neuron specific enolase; TTF-1, 
thyreoid transcription factor 1; CK, cytokeratin; CEA, Carcinoembryonic antigen; CYFRA 21-1 
cytokeratin 19 fragment. 
0 50 100 0 50 100 0 50 100 0 50 100
♂ ♀
0% 50% 100%
♂ ♀
0% 100%
♂ ♀
0% 100%
♂ ♀
0% 100%
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The summary provided in Table 3 is based on multiple recent studies (Barletta et al., 2009; 
Chen et al., 2009; Devesa et al., 2005; Janssen-Heijnen and Coebergh, 2001; Kenfield et al., 
2008; Molina et al., 2003; Noh and Shim, 2012; Russell et al., 2011; Sarrafzadegan et al., 
2007; Shibayama et al., 2001; Tacha et al., 2012). 
1.2 Therapeutical options with special regards to the tumor stroma 
The major challenge in lung cancer therapy arises from the fact that the majority of patients 
present with either locally advanced disease (stage III) or metastatic disease (stage IV). The 
first-choice approach is curative surgical resection. Importantly, patient survival ranges 
between 50% and 80% after surgery, implying that a significant number of patients require 
systematic treatment. Furthermore, occult and therefore untreated micrometastatic disease at 
the time of resection leads to relapse. Patients presenting with advanced disease, tumor 
relapse after surgery or metastatic spread are dependent on alternative therapeutic approaches. 
1.2.1 Radiation therapy 
Patients who are poor candidates for surgery because of their age, condition or advanced 
disease receive radiation treatment. Radiation is also used prior to surgery to shrink the tumor 
or maintain cells in a state of higher sensitivity to chemotherapeutic agents and therefore 
might be combined with chemotherapy. 
Moreover, radiation combined with chemotherapy is the treatment for SCLC, since this highly 
aggressive tumor tends to spread very quickly and eludes surgical treatment options (Stupp et 
al., 2004). 
1.2.2 Chemotherapy 
Chemotherapy (in combination with radiation) is the method of choice for advanced NSCLC, 
although chemotherapy regimens show only a modest improvement in survival and no 
regimen has been completely effective. Postoperative adjuvant chemotherapy has been shown 
to improve survival for patients with stage II disease and may also have a role in the treatment 
of stage IB NSCLC.  
Combination regimens, including platinum-based chemotherapy with either cisplatin or 
carboplatin, have become the standard of care for treating NSCLC, and these drugs modestly 
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improve survival (Arriagada et al., 2004). Various clinical trials failed to show an advantage 
of using more than two drugs in a chemotherapy regimen. First-line chemotherapeutic agents 
used in combination with cisplatin or carboplatin include taxanes (paclitaxel and docetaxel), 
gemcitabine (a deoxycytidine analogue), vinorelbine, and irinotecan or topotecan 
(topoisomerase I inhibitors).  
Therapy with chemotherapeutic agents is associated with severe side effects and significantly 
impairs the quality of the patient’s life. Even cisplatin and carboplatin, the mainstay of lung 
cancer chemotherapy, only increase the one-year survival to 30%, which appears relatively 
minimal if compared to the impact on the patient’s life. Overall, no chemotherapeutic agent or 
combination regimes showed a better one-year survival than the 40.3% reported with cisplatin 
together with paclitaxel (Bonomi et al., 2000; Crino et al., 1999; Haura, 2001; Le Chevalier et 
al., 1994; Sandler et al., 2000). This lack of success underlines the mandatory research to find 
alternatives to chemotherapy. 
1.2.3 Targeted therapy  
The most advanced approach of lung cancer therapy is targeted therapy. Thus far, only three 
pharmaceuticals have been approved for treatment of lung cancer in the past 10 years: 
gefitinib, erlotinib and crizotinib.  
As described above, NSCLCs exhibit genetic changes such as KRas mutations and EGFR-
abnormalities. Such genetic alterations can be detected in patients’ biopsies and provide a 
basis for a patient-optimized, targeted therapy. The first targeting agent to be approved for 
lung cancer treatment was gefitinib in 2002, and shortly after erlotinib in 2003. Both agents 
are tyrosine kinase inhibitors (TKIs) and designed to target EGFR mutations. An EGFR 
mutation is a valid biomarker of treatment response, and prospective clinical trials 
demonstrated a progression-free survival benefit of TKI as first-line therapy in EGFR mutant 
patients (Mok et al., 2009; Sharma et al., 2007). The EGFR mutation status can be determined 
by gene sequencing, in situ hybridization or immunohistochemistry with mutation-specific 
antibodies (Cagle and Chirieac, 2012). 
A second success for the approach of targeted therapies is crizotinib, which was approved in 
2011 and which was designed to target advanced or metastatic NSCLC that is positive for 
anaplastic lymphoma kinase (ALK). This tyrosine kinase receptor is usually expressed only in 
neuronal cell types. In NSCLC, ALK is rearranged to a protein with constitutive kinase 
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activity. Interestingly, none of the adenocarcinomas with rearranged ALK showed coexisting 
mutations of EGFR. A recently published clinical trial showed that lung cancers expressing 
ALK are sensitive to inhibitors of ALK kinase activity. Although only 7% of 
adenocarcinomas and nearly none of the squamous cell carcinomas show ALK mutations, 
crizotinib serves as an example for a successful targeted therapy (Koivunen et al., 2008; 
Kwak et al., 2010; Soda et al., 2007). 
More inhibitors for various genetic alterations are currently in clinical trials, such as 
trastuzumab, a chimerized monoclonal antibody against HER2/neu, a member of the human 
epidermal growth factor receptor family (Azzoli et al., 2002).  
Overall targeted therapy is a very promising approach, and in the future patients diagnosed for 
lung cancer will most likely be tested for a panel of oncogenes/mutations to optimize the 
therapy. Although the benefits of individualized therapy are obvious, one should consider 
both economic aspects and potential ethical questions. For example, what might be the 
consequence of a positive screen for lung cancer common mutations on the insurance status in 
countries without compulsory health insurance? 
1.2.4 Targeting the tumor microenvironment 
The tumor microenvironment surrounds the virtual tumor and consists of accumulated non-
neoplastic host cells, such as tumor-associated macrophages (TAM), cancer-associated 
fibroblasts (CAF), leucocyte subsets and non-cellular alterations including angiogenesis, 
abundant production of extracellular matrix (ECM) and secretion of cytokines and growth 
factors. Below is more detailed information regarding the tumor microenvironment (Figure 
2). 
Thus far, the only clinically approved therapeutic approach directed against the tumor 
microenvironment is bevacizumab (Avastin, Roche), a monoclonal antibody against VEGF. 
Overall, the survival benefits of antiangiogenetic drugs have been rather modest (Sounni and 
Noel, 2013). Moreover, therapy with bevacizumab requires an accurate diagnosis of the 
NSCLC subtype and is currently contraindicated in patients with lung squamous cell 
carcinoma, due to severe adverse side effects (bleeding complications) (Johnson et al., 2004). 
The only patient groups that benefit from bevacizumab treatment (and only in combination 
with chemotherapy) are those with non-squamous NSCLC. Furthermore, bevacizumab is not 
curative and treatment withdrawal leads to tumor regrowth (Sandler et al., 2006). 
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Since it is well-established that chronic inflammation contributes to cancer development, 
several studies have attempted to inhibit the inflammatory processes. A key pathway in 
inflammation is the activation of NF-κB, which leads to secretion of inflammatory cytokines. 
Chronic activation of NF-κB enhances resistance to chemotherapy and radiotherapy, and 
several NF-κB inhibitors have been reported to improve the effect of chemotherapeutic agents 
against lung cancer and induce tumor regression and prolonged survival in mice. However, 
sustained NF-kB inhibition results in neutrophilia, enhanced acute inflammation and liver 
damage (Greten et al., 2007; Izzo et al., 2006; Xue et al., 2011). 
An approach to directly target stromal cells was developed with sibrotuzumab, a humanized 
monoclonal antibody against FAP (fibroblast activation protein α), a membrane-bound serine 
protease expressed by CAFs. Immunohistochemical studies revealed that FAP is mainly 
localized in the stroma of tumor cells, but not in the stroma of healthy tissue, thus providing a 
potential cancer-specific target. However, phase I and II studies targeting FAP failed to show 
clinical benefits (Xing et al., 2010). 
Several researchers employed a completely different strategy, whereby instead of targeting 
specific stromal cells, the immune system was manipulated with the aim of overcoming tumor 
-mediated immune suppression. Tumor cells are known to thrive in an immunosuppressed 
environment. In normal cells, antigen-presenting cells (APCs) phagocytes tumor cell 
fragments and display the antigens on their surface to naïve T-lymphocytes in adjacent lymph 
nodes, which in turn are activated to tumor-specific CD4+ T-helper and CD8+ cytotoxic T-
cells. This process is abrogated in lung cancer development (Gridelli et al., 2009; Kelly et al., 
2010). Several groups attempted to restore this co-stimulatory pathway with approaches such 
as vaccine therapy or antigen-independent immunotherapy. The most successful tumor-
antigen based vaccine was L-BLP25 against MUC-1 (mucin-1), which is overexpressed in 
various cancers. However, it eventually failed in clinical phase II studies (Butts et al., 2005; 
Sangha and Butts, 2007). Dendritic cells (DCs) vaccines are based on DCs cultured with 
necrotic tumor cells or electroporated tumor lysates and injected either intradermally or into 
the patient’s lymph nodes. These vaccines seem to be tolerated in patients with NSCLC and 
are currently in phase I studies. This therapy approach is individualized for patients and 
accordingly economically difficult to accomplish (Chang et al., 2005; Um et al., 2010).  
Antigen-independent therapy appears to be a more feasible option, and two approaches are 
currently in advanced clinical trials. The first involves ipilimumab, a humanized IgG1 anti-
CTLA-4 antibody (cytotoxic T-lymphocyte antigen 4, CD152), which binds a receptor that 
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induces downregulation of the immune system upon stimulation. Ipilimumab blocks this 
inhibitory signal and thus enhances and prolongs the activation and proliferation of tumor-
specific T-cells (Fong and Small, 2008; Tarhini and Iqbal, 2010) Ipilimumab was found to 
improve the survival in metastatic melanoma patients in a phase III clinical study (Hodi et al., 
2010).  
A similar approach for improving the immune reaction again tumor cells is provided with 
talactoferrin alfa, a recombinant human lactoferrin that enhances the movement of immune 
cells to lymphoid tissue, where it stimulates their maturation. This leads to increased levels of 
DCs bearing tumor antigens, as well as secretion of cytokines that promote maturation and 
proliferation of antitumor CD8+ T-cells. Talactoferrin alfa demonstrated a significantly 
improved median overall survival in a phase II trial with NSCLC patients (Digumarti et al., 
2011; Parikh et al., 2011).  
 
1.3 The tumor microenvironment 
1.3.1 Characterization of the tumor microenvironment 
Over recent decades, the conventional view of tumorigenesis as a cell-autonomous process 
based solely on genetic mutations has shifted, as experimental evidence has revealed that the 
presence of mutations alone is not sufficient for primary tumor growth and metastasis. 
Moreover, it has become increasingly apparent that non-neoplastic host cells present in solid 
tumors play a key role in achieving and promoting an oncogenic microenvironment with 
dynamic and sustained signaling cascades. The most important microenvironmental 
alterations include the accumulation of TAMs, CAFs and various leucocyte subsets, as well as 
non-cellular alterations such as neoangiogenesis, abundant production of ECM, and secretion 
of cytokines and growth factors (Cavallo et al., 2011; Coussens and Werb, 2002; Hanahan and 
Weinberg, 2000).   
While the co-dependent relationship that exists between tumor and stromal cells is well-
documented, the regulatory pathways that underlie these interactions are not well understood. 
A better understanding of the crosstalk between cancer cells and their tumor stroma will likely 
provide new therapeutic targets. This knowledge is invaluable, since the currently available 
chemotherapeutic agents are not efficacious, particularly in the case of lung cancer. 
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Figure 2 The tumor microenvironment. CAF, Cancer associated fibroblast; ECM, Extracellular Matrix; 
N1/N2, Neutrophil-polarization; M1/M2, Macrophage-polarization; RNS, reactive nitrogen species; ROS, 
reactive oxygen species; TAN, Tumor associated Neutrophil; TAM, Tumor associated Macrophage; TH1/TH2, 
T-Lymphocyte-polarization; Tcyt, cytotoxic T-Lymphocyte. 
 
Cancer-associated fibroblasts (CAF) 
CAF are the most prominent cell type within the tumor stroma and are divided into several 
subpopulations based on their derivation and marker expression. CAF can derive from 
resident local interstitial fibroblasts, bone marrow-derived progenitor cells or trans-
differentiating epithelial cells (Anderberg and Pietras, 2009). Most overlapping markers for 
CAF are α-smooth muscle actin (SMA), platelet-derived growth factor receptors (PDGFR) 
and fibroblast specific protein-1 (FSP-1) (Sugimoto et al., 2006). CAF promote tumor cell 
proliferation via secretion of hepatocyte growth factor (HGF), fibroblast growth factors 
(FGF), Wnt-family members and CXCL12 and further convey cancer cells by producing anti-
apoptotic stimuli such as insulin-like growth factor-1 and -2 (Bhowmick et al., 2004; Strnad et 
al., 2010). Moreover, they abundantly supply the ECM with different collagens and their 
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tumor-promoting capacities were demonstrated in several in vivo studies (Anderberg et al., 
2009; Karnoub et al., 2007). Interestingly, CAF display a different phenotype compared to 
normal fibroblasts (Chaudhri et al., 2013). 
 
Pericytes 
Pericytes are crucial for maturation and stabilization of vessels. However, pericytes localized 
in the tumor microenvironment appear to have a more loosely attached phenotype and fail to 
interact properly with endothelial cells, resulting in leaky and disorganized vessels, which 
might promote metastatic spread (Morikawa et al., 2002; Xian et al., 2006). 
 
Myeloid leukocytes  
Cells of myeloid origin such as mast cells, granulocytes (neutrophils, basophils and 
eosinophils), DCs, macrophages (MΦ) and monocytes (MC) are abundantly accumulated in 
pre-malignant and malignant tissues. They orchestrate a myriad of signaling cascades by 
releasing cytokines, chemokines, matrix metalloproteinases, serine proteases, reactive oxygen 
species (DNA damage!), histamine and other bioactive mediators, which influence tissue 
remodeling and angiogenesis and as a consequence tumor cell migration and metastasis 
(Coukos et al., 2005; Coussens et al., 1999; De Palma and Naldini, 2006). Whereas the 
contributions of basophils and eosinophils to lung cancer development are less intensively 
studied, recent data suggest that tumor associated neutrophil (TAN) subpopulations show a 
Janus face similar to different polarized MΦ, i.e. they can be divided into a N1-tumor limiting 
and a N2-tumor promoting fraction. Key cytokines in TAN polarization include TGFβ 
(promoting N2) and IFNβ (promoting N1). Typical characteristics of N1 are a hyper-
segmented nucleus and restriction of angiogenesis. The N1 subpopulation is highly cytotoxic 
due to secretion of proteases, ROS and RNS (reactive oxygen species and reactive nitrogen 
species). The N2 subpopulation is identified by circular nuclei. Similar to MΦ sub-
populations, they promote angiogenesis, invasiveness and metastasis of lung cancer cells 
(DeNardo et al., 2010; Piccard et al., 2012).   
The involvement of mast cells in tumor progression and rejection remains overall 
controversial. Immature mast cell progenitors are released from the bone marrow and remain 
circulating. They mature as they migrate into tissue, with adapting tissue specific 
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characteristics that guide a division of mast cells into two general subtypes: connective tissue 
mast cells with chymase expression and mucosal mast cells with tryptase expression, such as 
abundantly found in the mucosa of the lungs (Irani et al., 1986). In NSLC, mast cells and mast 
cell-derived histamine were shown to increase proliferation and tumor growth in a histamine 
receptor dependent pathway (Stoyanov et al., 2012). Controversially, studies with non-small 
cell lung cancer patients demonstrated a correlation of low microenvironmental infiltration of 
mast cells with a worse prognosis (Carlini et al., 2010) and abundant accumulation of mast 
cells in tumor islets with an improved prognosis (Welsh et al., 2005) 
 
Lymphoid leukocytes 
Accumulation of the lymphocyte subpopulation described thus far can be observed in the 
tumor microenvironment. There are two distinct subpopulations: the CD8+ cytotoxic T-
lymphocyte and NK (natural killer) cells, with a more clarified role in lung cancer 
development. Both cell populations play a critical role in restraining tumor progression (Dunn 
et al., 2004). This tumor-restraining effect might be masked by other lymphocyte populations, 
as in the entire tumor stroma the balance between both forces is critical and the dominating 
effect dictates tumor-progression or -regression  (Balkwill et al., 2005; de Visser et al., 2006; 
Karin et al., 2006).  
The contribution of CD4+ T-cells, the most prominent T-cell subset, is quite controversial. 
Infiltration of CD4+ cells in human lung cancer tissue correlates with a positive outcome, 
whereas in other cancer types, CD4+ accumulation is associated with a decreased survival rate 
(Siddiqui et al., 2007; Wakabayashi et al., 2003). The two subpopulations of CD4+ cells, TH1 
and TH2 cells, might explain these controversial effects. Polarization towards TH1 or TH2 is 
determined by different cytokines. In general, TH1 cells maintain tumor restrictive processes, 
such as enhancing APCs and prolonging the response of CD8+ cytotoxic cells (Romagnani et 
al., 1997). They are further able to kill tumor cells directly by secreting IFNγ, TNFα and 
cytolytic granules (Munk and Emoto, 1995). TH2 cells release abundant amounts of IL-4, IL-
10 and IL-13, which promote tumor growth indirectly by favoring MΦ-polarization towards 
an M2-phenotype, inhibiting apoptosis and inducing proliferation. 
 In conclusion, it is the ratio of TH2 to TH1-cells that correlates more consistently with 
parameters of clinical disease progression and thus is more important than an overall 
determination of infiltrating CD4+ lymphocytes in cancer tissue (Chin et al., 1992).  
Introduction 
 
19 
 
Another subpopulation thought to play a role in regulating tumor progression is the 
CD4+FoxP3+ T regulatory (TREG) cell population. TREG-infiltrations in NSCLC correlate with 
a poor prognosis (Petersen et al., 2006), and these cells seem to influence tumor development 
via suppression of the anti-tumor activities of CD8+ cytotoxic lymphocytes, NK-cells and DC 
(Fehervari and Sakaguchi, 2004; Trzonkowski et al., 2004). Obviously, TREG cells shift the 
cytokine secretion pattern towards immunosuppressive-acting cytokines such as TGFβ, IL-35 
and IL-10, and further interfere with the metabolic activity of cyclic adenosine 
monophosphate (cAMP) transfer, as well as inhibiting APC function by inducing binding of 
cytotoxic T-lymphocytes to CD80/86, which is necessary for T-cell activation and survival 
(Strauss et al., 2007; Tang and Bluestone, 2008).  
A more recently discovered T-cell subset is the TH17-cell group that differentiates upon 
stimulation of IL-6 and TGFß and mediates their effect through secretion of IL-17, IL-21 and 
IL-22 (Dong, 2008; Weaver et al., 2006). Secretion of IL-17 promotes the growth of NSCLC 
in a mouse model by enhancing neoangiogenesis (Numasaki et al., 2003; Numasaki et al., 
2005). 
 
Extra-cellular Matrix (ECM)  
Although not an active cellular component of the tumor stroma, the ECM plays a crucial role 
in tumor progression and migration. Collagen is the most abundantly expressed protein in the 
ECM, and its crosslinking results in ECM stiffening, thus facilitating tumor growth, invasion 
and metastatic spread (Levental et al., 2009; Lo et al., 2000). 
1.3.2 Macrophages (MΦ) in the tumor microenvironment 
MΦ represent a key component of the innate immune system, with effector functions that are 
far beyond their classical functions as phagocytic and antigen-presenting immune cells. With 
their plasticity and ability to secret a wide variety of cytokines, chemokines, growth factors 
and enzymes, they are major players in regulating tissue homeostasis both in normal 
physiological and pathophysiological conditions (Mosser and Edwards, 2008; Murray and 
Wynn, 2011). Accumulated MΦ in tissue can have different origins: (1) they derive from 
proliferation of local tissue MΦ, (2) they differentiate from myeloid progenitors from the 
bone marrow over a monocyte state to MΦ or (3) they differentiate from splenic monocytes. 
Introduction 
 
20 
 
Several tissues have more than one resident MΦ population, mostly with different              
functions. In the lung, for example, alveolar MΦ reside on alveolar septae in the alveolar 
space, and alveolar interstitial MΦ reside in the interstitium of the lung (Cortez-Retamozo et 
al., 2012; Galli et al., 2011; Kugathasan et al., 2008; Laskin et al., 2001). MΦ have been 
shown to enhance tumor growth in a variety of cancers, including breast, prostate, colorectal 
and hepatocellular carcinomas (Cortez-Retamozo et al., 2012; Mroczko et al., 2007; Qian and 
Pollard, 2010; Zhu et al., 2008). In addition, enhanced infiltration of MΦ within tumors is 
associated with a poor outcome and shorter survival times. In contrast, it is well-documented 
that directed activation of immune cells leads to cancer regression (Aarntzen et al., 2012; 
Freire and Osinaga, 2012; Nars and Kaneno, 2012; Savai et al., 2007). Hence, an      
ambiguity remains regarding the role of MΦ in cancer initiation and progression. Part of this     
ambiguity may be explained by the fact that MΦ can polarize into either pro-inflammatory 
(M1) or “alternatively activated” anti-inflammatory (M2) cells (Figure 3). The M1-phenotype 
develops upon contact with LPS or bacteria, IFNγ or activation of Toll-like receptors (TLR). 
In response, iNOS expression and activity is upregulated to produce reactive oxygen or 
nitrogen species, histamine and proteolytic enzymes to kill microorganisms. Furthermore, 
classical pro-inflammatory cytokines are upregulated, such as IL-1β, IL-12, IL-6 and an 
overall inflammatory reaction, including activation of NK-cells and TH1 response is induced. 
In the context of cancer development, M1 cells were considered the “good guys” with        
tumor-restrictive properties that are mainly based on tumor antigen presentation and 
phagocytosis of malignant cells. M2-polarization was recently divided into more subtypes, 
such as M2a, M2b and M2c, based on cytokine secretion patterns. However, all M2-subtypes 
have tumor supporting features in common, so MΦ will be considered to divide only into M1 
and M2. MΦ polarize into M2 upon stimulation with cytokines known of a TH2-immune 
response, such as IL-4, IL-13, IL-33 and IL-10. Furthermore, MΦ can adapt an M2-phenotype 
upon interaction with B-cells, which secrete immune complexes in combination with IL-1β 
and IL-10. With polarization to an M2-phenotype, the ability of tumor restriction is lost and 
M2-MΦ work as anti-inflammatory agents and strongly promote angiogenesis and tissue               
remodeling. M2-MΦ express arginase1 and CD206, and secrete high levels of IL-10 and IL-
RA. MΦ-polarization can be retraced to their progenitor monocytes and is even reflected in 
certain signal transduction patterns with distinct kinases and transcription factors as 
summarized in Figure 3 (Biswas and Mantovani, 2010; Lawrence and Natoli, 2011; Sica et 
al., 2008).  
Introduction 
 
21 
 
 
Figure 3 Summary of MΦ-polarization (above MΦ: stimuli, intracellular: signal transduction pathways; 
under MΦ: target genes). Arg1, arginase 1; Chi3l3, chitinase 3-like 3; CREB, cAMP-responsive element-
binding protein; GM-CSF, granulocyte-macrophage colony stimulating factor; GR, galactose receptor; IFNγ, 
interferonγ; iNOS, inducible NO-synthase; IL, interleukin; IRF, Interferon-regularoty factor; JAK, Janus 
kinase; LPS, lipopolysaccharide; M-CSF, macrophage colony stimulating factor; MSK, mitogen- and stress-
activated kinase; MR, mannose receptor; NF-κB, nuclear factor-κB; PI3K, phosphoinositied 3-kinase; PPARγ, 
peroxisome proliferator-activated receptor γ; RNS, reactive nitrogen species; ROS, reactive oxygen species; 
STAT, signal transducer and activator of transcription; SR, scavenging receptor; TLR4, toll-like receptor 4 
[adapted from (Biswas and Mantovani, 2010; Lawrence and Natoli, 2011) 
Although some research was done in the field of MΦ-polarization, there is still no validated 
marker specific for M2-MΦ, and overall marker expression often displays heterogeneity 
between M1 and M2-markers (Gordon and Martinez, 2010; Mantovani et al., 2002). These 
observations suggest that MΦ-polarization is dynamic and the effector functions of discrete 
MΦ populations are incompletely understood. Due to the heterogeneity of MΦ subpopulations 
(especially in vivo) and their pleiotropic effects, research with MΦ has proven challenging, 
especially in a setting such as lung cancer where long-term studies are required. 
1.4 Chemokine receptors CCR2 and CX3CR1 
MΦ direct distinct cytokine- and chemokine -networks in various, mainly inflammatory 
diseases. Two important chemokine receptors within these networks are CCR2, the receptor 
for CCL2 (MCP-1, monocyte chemoattractant protein 1) and CX3CR1, the receptor for 
CX3CL1 (Fractalkine, Neurotactin). The chemokine receptor nomenclature reflects their 
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binding ligands, which are named based on the number and location of the cysteine residues 
at the N-terminus of the molecule. (Figure 4). 
 
 
Figure 4 Structure and ligands of CCR2 and CX3CR1 [modified after (Burke-Gaffney et al., 2002)]. 
CCR2 exists in two isoforms, CCR2A and CCR2B, and both are encoded by a single CCR2 
gene. The isoforms are derived by alternative splicing and gene-sequencing uncovered, that 
the 47-amino acid carboxyl tail of CCR2B was located together with the seven 
transmembrane domains in the same exon, and the 61-amino acid tail of CCR2A was in a 
downstream exon. Accordingly, the splicing variants differ only in their terminal carboxyl 
tail. Both isoforms are G-protein-coupled receptors and bind CCL2 with high affinity. The 
differences in the terminal carboxyl tail result in a different signal transduction and 
localization of the receptor. Binding of the agonist CCL2 results in a rapid Ca2+ (Calcium) 
influx after activation of CCR2B, but not CCR2A. Moreover, the trafficking to the membrane 
of CCR2A is impaired, implying that the amino acid sequence responsible for the receptor 
localization is within the terminal carboxyl tail. Finally, CCR2B is the more abundantly 
expressed receptor overall and the low expression of CCR2A makes studies challenging, so 
that the exact functions of this splicing variant remain unclear. (Sanders et al., 2000; Wong et 
al., 1997) In the following explanations CCR2 refers to the isoform CCR2B. Additionally to 
CCL2, studies revealed CCL7 (MCP-3, monocyte chemoattractant protein 3), CCL8 (MCP-2, 
monocyte chemoattractant protein 2) and CCL13 (MCP-4, monocyte chemoattractant protein 
4) as agonists of CCR2 (Figure 4). However, CCL2 is the ligand with the highest affinity and 
potency, as measured as Ca2+ flux. Moreover, CCL2 amplifies its own receptor binding 
affinity via CCR2 binding (Kito et al., 2001; Moore et al., 1997; Uguccioni et al., 1995).  
Although three isoforms are reported for CX3CR1 – the “standard” and two prolonged amino 
acid sequences - , the functional differences are poorly investigated. However, the extended 
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isoforms display an increased sensitivity upon CX3CL1 binding with increased Ca2+ 
mobilization (Garin et al., 2003). The only CX3-chemokine, CX3CL1 binds exclusively to 
CX3CR1, thus implying a tighter regulation of CX3CR1-CX3CL1 signaling as compared to 
CCR2-CCL2 signaling (Deshmane et al., 2009; Rodriguez-Frade et al., 1999). 
Both, CCR2 and CX3CR1 are transmembrane G-protein coupled receptors, which activate 
multiple signaling pathways including JAK-STAT, MAPK and PI-3K pathways, upon 
dimerization (Mellado et al., 1998; Wolf et al., 2012). Agonist-mediated activation leads to 
chemotaxis of CCR2-expressing cells towards the CCL2 concentration gradient. In contrast, 
CX3CR1-CX3CL1 binding leads not only to chemotaxis but also to integrin independent 
adhesion of the CX3CR1-expressing cell, since CX3CL1 can be expressed as a membrane-
bound protein as well as a cleaved and then chemotactic peptide. This dual function is unique 
in the group of chemokines (Kim et al., 2011). CX3CR1-CX3CL1 signaling is further 
important for angiogenesis and proliferation (Imai et al., 1997; Lee et al., 2006). Both 
receptors are expressed abundantly by MΦ and monocytes as well as other leucocytes. 
CCL2-CCR2 and CX3CL1-CX3CR1 signaling plays a crucial role in many inflammatory 
diseases where chemotactic attraction of immune cells to the site of inflammation is crucial 
and a lack of CCR2/CX3CR1 results in decreased MC/MΦ-accumulation. CCR2-mediated 
emigration of MC from the bone marrow to the blood stream and following trafficking to the 
foci of infection is important for clearance of several bacteria, viruses, fungi and protozoa. 
However, persistent accumulation of CX3CL1/CCL2-attracted inflammatory cells results in 
chronic inflammation, severe tissue destruction and remodeling. For example, high CX3CL1-
levels are associated with COPD, pulmonary hypertension and pulmonary fibrosis in a 
negative sense (Shi and Pamer, 2011; Zhang and Patel, 2010).  
The importance of CCL2 in tumor growth and metastasis was demonstrated in several types 
of cancers, with the focus on CCL2-secreting cancer cells. The main discovery in most of the 
studies was that CCL2 attracts monocytes to establish a tumor microenvironment (Bailey et 
al., 2007; Erreni et al., 2010; Qian et al., 2011; Tanaka et al., 2009).  
Overall, the role of CX3CL1 in cancer progression is more contrary. CX3CL1 and CX3CR1 
were found to be expressed and functional on glioma cells but inhibited invasiveness of 
cancer cells. In contrast, another study could correlate high CX3CL1-expression with a later 
stage and worse survival in oligodendrogliomas, anaplastic astrocytomas and glioblastomas. 
Furthermore, CX3CL1 expression in breast cancer tissue correlates with a poor outcome. 
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Additionally, CX3CL1 was able to promote cancer development in a spontaneous model of 
breast cancer by activating EGF signaling. (Erreni et al., 2010; Sciume et al., 2010; 
Tardaguila et al., 2013; Tsang et al., 2013) 
However, the role of chemokine receptors, CCR2 and CX3CR1, as well on MΦ or cancer 
cells during cancer progression and metastasis, is poorly understood. 
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2 Aims of the Study 
 
Lung cancer is the leading cause of cancer death worldwide. This high death rate in relation to 
newly diagnosed lung cancer cases is due to (1) advanced stage of the disease at the time of 
diagnosis without possibility of resection, (2) failure of existing chemotherapeutic acting 
agents especially in late stage and metastatic lung cancer and (3) the lack of reliable 
preventive screenings. One of the important reasons for these dilemmas is the lack of 
knowledge of the underlying mechanisms of lung cancer development and progression 
besides the triggering mutations of oncogenes. In particular, the involvement of the tumor 
microenvironment with innumerable interacting cell types and signaling cascades remains 
unclear.   
The present study was performed to contribute to elucidate dysregulated key pathways in the 
tumor microenvironment with particular attention to MΦ-tumor cell interactions. This study 
was conducted to 
(1) Determine the magnitude of contribution of different MΦ-populations to tumor growth 
and metastasis. 
(2) Determine fundamental mechanisms of MΦ-contribution to the tumor microenvironment. 
(3) Identify aberrant signaling pathways in MΦ and cancer cells provoked by their 
interactions. 
(4) Identify new targets for anti-cancer drugs apart from chemotherapeutic agents to treat lung 
cancer. 
These aims were accomplished using long-term MΦ-depleted animal models, pathway- 
specific knockout animals and in vitro co-cultures of MΦ and cancer cells. 
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3 Materials and Experimental Procedures 
3.1 Experimental procedures – in vitro 
3.1.1 Cell culture 
Murine lung cancer cell line 
Experimental analyses were performed using the LLC1 (Lewis lung carcinoma 1) cell line, 
which was originally established from a Lewis lung carcinoma bearing C57/Bl6 mouse. 
Although this cell line originated from a distinct epithelial background, some epithelial 
characteristics were lost due to its malignant transformation. This results in a mixed 
morphology, with a more elongated and attached as well as rounded cell population that 
grows in suspension. 
The LLC1 cell line is an ideal tool for investigating the development of lung cancer in vitro 
and in vivo since it is syngeneic with the C57/Bl6 mouse, which is the basis for genetically 
modified animals such as Knock out and transgenic mice. LLC1 cells are highly tumorigenic 
in mice with a well reproducible tumor growth curve and the ability to form metastasis. 
(Bertram and Janik, 1980). LLC1 cells were obtained from the American type culture 
collection (ATCC; CRL-1642™ ) and were cultured in tissue culture flasks in RPMI 1640 
supplemented with 1% glutamine, 10% fetal calf serum (FCS) and penicillin (100U/ml) 
/streptomycin (0.1 mg/ml). Subcultures were prepared by aspirating the media, washing the 
cells once with 1× phosphate buffered saline (PBS) and incubating cells at 37°C with 1× 
Trypsine. After cell detachment FCS was added to stop the reaction and the cell suspension 
was centrifuged for 8 min at 1600 rpm. After subsequent resuspension in fresh media, the 
cells were plated again at a ratio of 1:6. Excessive cells were frozen as stock in liquid nitrogen 
for later use: one million LLC1 cells were resuspended in 1 ml of the culture media 
supplemented with 5% DMSO and stored in screw cap cryotubes overnight in an isopropanol 
filled freezing box at -80°C. The next day all cryotubes were moved to the liquid nitrogen 
storage tank. 
Human lung cancer cell lines 
Every human lung cancer cell line was cultured, subcultured and frozen analogue to the 
LLC1. A summary of media, histological subtype and ATCC-Nr is provided in  
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Table 4. 
Cell Line ATCC-No. Media Histological subtype 
A549 (ATCC® CRL-5800™) DMEM/F12 Adenocarcinoma 
H23 (ATCC® CRL-5800™) DMEM/F12 Adenocarcinoma 
H226 ATCC® CRL-5826™) DMEM/F12 Squamous cell carcinoma 
H460 (ATCC® HTB-177™) RPMI 1640 Large cell lung cancer 
H520 (ATCC® HTB-182™) RPMI 1640 Squamous cell carcinoma 
H661 (ATCC® HTB-183™) RPMI 1640 Large cell lung cancer 
H1299 (ATCC® CRL-5803™) DMEM/F12 Adenocarcinoma 
H1437 (ATCC® CRL-5872™) RPMI 1640 Adenocarcinoma 
H1650 ATCC® CRL-5883™) RPMI 1640 Adenocarcinoma 
H1975 (ATCC® CRL-5908™) RPMI 1640 Adenocarcinoma 
 
Table 4 Human lung cancer cell lines 
DMEM/F12 media was supplemented for all cell lines with 10% FCS, 1% penicillin 
(100U/ml) /streptomycin (0.1 mg/ml), 1% vitamins, 1% Glutamine and 1% non-essential 
amino acids.  RPMI 1640 was supplemented for all cell lines with 10% FCS, 1% penicillin 
(100U/ml) /streptomycin (0.1 mg/ml), 0.11 g/l NatriumPyruvat and 2.383 g/l HEPES ((4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid).  
 For cell culture experiments or injections, a single cell suspension was prepared by 
trypsinizing cultured cells as above and resuspending them in fresh media. Cells were counted 
with a Neubauer counting chamber and viable cells were distinguished with trypan blue 
staining. The cell concentration was adjusted for the according experiment by dilution with 
the necessary amount of fresh media. DMEM/F12, RPMI1640, L-glutamine, vitamins, non-
essential amino acids, HEPES, NatriumPyruvat,  trypsin 10×, FCS, penicillin (100U/ml) 
/streptomycin (0.1 mg/ml), trypan blue stain, PBS 1×, all cell culture materials (e.g. cell 
culture flasks) were purchased from Gibco® life technologies, Grand Island, USA. DMSO 
was purchased from Sigma-Aldrich, St. Louis, USA. 
3.1.2 Lentiviral transduction of LLC1 
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Lentiviral vectors (pLKO.1-puro) containing short hairpin RNAi against mouse CCR2 and 
CX3CR1 were obtained from Mission shRNA®, Sigma-Aldrich. Scramble shRNA and empty 
vector pLKO.1-puro vector (Addgene plasmid 8453) were used as a negative control. 
Lentivirus particles were produced by co-transfection of HEK293T cells (obtained from 
ATCC) with lentiviral plasmid and packing plasmid (psPAX2 and pMD2.G) using TurboFect 
transfection reagent (Fermentas). Supernatants were collected 72 h after transfection (Stewart 
et al., 2003). Lentivirus titers were determined with the QuickTiters lentivirus titer kit, an HIV 
p24-based ELISA (Cell Biolabs), according to the supplier’s procedure. LLC1 cells were 
cultured in 75 cm2 flasks and transduced with lentivirus (multiplicity of infection (MOI) = 50) 
in the presence of 7 µg/ml polybrene (Sigma-Aldrich). Twenty-four hours after infection, 
medium was replaced with fresh medium for 48h and experiments were performed. 
3.1.3 Generation of bone marrow derived MΦ 
Bone marrow from the femur and tibia of 5- to 7-week old wild type (WT), CCR2-/- or 
CX3CR1-/- mice were isolated, erythrocyte-depleted and cultured for 10 days in RPMI 1640 
(20% FCS, 1% penicillin/streptomycin) in the presence of 50 ng/ml recombinant murine 
macrophage stimulating factor (rmM-CSF, R&D Systems, Minnesota, USA) (Figure 5). After 
10 days, cells were harvested and used for co-culture experiments described above. Purity and 
correct differentiation were screened by Flow cytometry (FACS) and immunocytochemistry. 
 
Figure 5 Generation of bone-marrow derived macrophages 
3.1.4 Polarization of bone-marrow derived MФ 
To generate M1- or M2 polarized MΦ as a positive control for polarization studies or in vivo 
injection in mice, bone marrow generated MФ were polarized in vitro. Two well established 
methods to generate MΦ are in vitro generation with either M-CSF (macrophage-colony 
stimulating factor) or GM-CSF (granulocyte/macrophage colony stimulating factor). Recent 
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data show that growth factors determine polarization of MΦ towards M1 (GM-CSF) or M2 
(M-CSF), (Fleetwood et al., 2009). MΦ were generated with 20ng/ml rmGM-CSF (R&D 
Systems) and additionally treated with 100 ng lipopolysaccharide (LPS) from E.coli (Sigma-
Aldrich) to obtain an M1-phenotype. To polarize the MФ towards an M2-phenotype, MФ 
were generated with 50 ng/ml rmM-CSF as described and stimulated with a combination of 
10 ng/ml IL-4 and 10 ng/ml IL-13 (R&D Systems). Polarized MФ were harvested and 
prepared for RNA-isolation or in vivo injection. 
3.1.5 Generation of human monocyte derived MΦ 
Buffy coats for isolation of peripheral blood mononuclear were obtained from the blood bank 
of the university hospital Gießen. The peripheral blood was mixed with culture media 
(DMEM/F12) in a 1:2 ratio. The mixed blood was carefully overlayed on Ficoll (BIOCOLL, 
Biochrom AG, Berlin, Germany). After a centrifugation without breaking for 20 min, the 
interphase of white blood cells was transferred in a new falcon with 5 ml media. After 
additional centrifugation (with breaks), cells were counted and prepared for antibody-
mediated depletion of B-cells and T-cells. 
Magenetic beads (Dynabeads®, life technologies) were washed three times with o.1% BSA in 
PBS. First, a CD2-antibody was added to deplete T-Cells. After incubation, cells were washed 
and Dynabeads were added. After an incubation of 30-45 min, the tube was placed in a 
magnet holder for 1 min and unbound cells were removed. In a second depletion step, CD19-
antibody was added to remove B-Cells. After incubation, washing and addition of Dynabeads, 
the tube was placed in a magnet holder for 1 min and unbound cells were removed, washed 
and counted. Finally, cells were cultured in flasks in RMPI 1640, supplemented with 20% 
FCS and 20 ng/ml recombinant human M-CSF for 8-10 days (rhM-CSF, R&D Systems). For 
experimental use, MΦ were gently harvested with a rubber cell scraper (Sarstedt, Inc.; 
Newton, USA), washed and seeded for the according experiment.  
3.1.6 Co-culture 
Co-culture of LLC1 and MΦ from either WT, CCR2-/- or CX3CR1-/- mice was performed 
using a transwell system with a 6-well layout. First, LLC1 cells were seeded on inverted 
transwells (pore size 8 µm, BD BioSciences, Franklin Lakes, USA), left two hours to attach 
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and placed in companion plates (BD Biosciences). After 24 h MΦ were seeded in new 
companion plates and combined with the LLC1-populated transwells (Figure 6).  
 
Figure 6 Co-culture of LLC1 with macrophages 
LLC1 and MΦ were seeded separately as controls. All cells were cultured in RPMI-1640 
supplemented with 1% FCS and penicillin (100U/ml) /streptomycin (0.1 mg/ml). After 12 h 
and 24 h, the supernatant (conditioned media; CM) was harvested, centrifuged, filtered and 
stored at –80°C for further experiments. Additionally, each cell type was harvested separately 
from the transwell filters (LLC1) or the companion plate (MΦ) and prepared for RNA-
isolation.  This resulted in following samples: 
A. conditioned media (CM): MΦ alone, LLC1 alone, co-culture of LLC1 and MΦ. 
B. mRNA: MΦ alone, LLC1 alone, co-cultured LLC1 and co-cultured MΦ. 
Each sample set was replicated at 3-5 times from co-cultures with MФ from WT, CCR2-/- and 
CX3CR1-/- mice. 
Human cancer cells were co-cultured analogue to LLC1 with human MC-derived MΦ for 24 
h. All human cancer cells and MΦ were cultured in DMEM/F12 supplemented with 1% FCS 
and penicillin (100U/ml) / streptomycin (0.1 mg/ml). After co-culture, CM  and each cell type 
were collected as described for LLC1/ MΦ co-cultures for further analysis. 
3.1.7 Flow cytometry 
Multiparameter flow cytometer analysis of MΦ was performed using a FACSCanto flow 
cytometer equipped with DIVA software (BD Biosciences). Cells (5x105) were fixed for 15 
minutes in cold 1% paraformaldehyde and incubated with fluorochrome labeled antibodies 
(CD45-APC-Cy7, GR-1-PE-Cy7, CD11b-PE, CD11c-PerCP-Cy5.5, F4/80-APC, MHC II-
FITC, all BD Biosciences) for 20 min at 4°C. After two washes in FACS buffer (PBS-/- 
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supplemented with 7.4 % EDTA and 0,5 % FCS) the cells were subjected to flow cytometric 
quantification of MΦ(CD45+ GR1low/neg CD11b+ CD11c+ F4/80+ MHC IIlow). 
3.1.8 RNA isolation, DNaseI treatment, cDNA-synthesis, real time RT-PCR 
RNA was isolated using Trizol® Reagent (Invitrogen, Carlbad, CA, USA) according to 
manufacturer`s instructions. Trizol® is based on the method of Chomczynski and Sacchi and 
contains guanidiniumthiocyanate for cell lysis and inactivation of RNAses and phenol to 
dissolve DNA and protein. After phaseseparation by addition of chloroform and 
centrifugation, total RNA was precipitated with isopropanol from the resulting aqueous phase. 
Concentration and purity of the RNA was measured with NanoDrop (Peqlab Biotechnologie 
GmbH, Erlangen, Germany) and integrity of RNA was monitored with 1% agarose gels. 
To avoid any DNA contamination in the real time RT-PCR reactions, all RNA-samples were 
treated with DNaseI under following conditions: 
RNA [0.1 µg/µl] µl 
DEPC-H20 30 µl – X 
MasterMix 1 
Buffer 4 
RNAse Inhibitor 1 
DNAseI 4 
 
Table 5 DNAseI treatment 
All samples were incubated at 37°C for 30 min. In the last step, 4 µl EDTA (25 mM) were 
added and each tube was incubated for 10 min at 65°C to inactivate DNAseI. All reagents 
were purchased from Fermentas (Waltham, USA).  A total of 800 ng of total RNA was 
reverse transcribed using the ImPromII-Kit (Promega, Madison, USA) according to supplier’s 
instructions.   
Real time RT-PCR was performed with the Platinum®SYBR®Green qPCR SuperMix-UDG 
(Invitrogen, Life Technologies, Grand Island, USA) and the following conditions: 
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Master Mix Volume Final concentration 
Platinum®SYBR®Green qPCR SuperMix-UDG 12.5 µl 1x 
MgCl2 [50mM] 1 µl 5 mM 
Forward primer [10µM] 0.5 µl 0.1 µM 
Reverse primer [10µM] 0.5 µl 0.1 µM 
ROX reference dye [25µM] 0.1 µl 0.1 µM 
cDNA [0.25µg/µl] 2 µl 0.5 µg 
DEPC-H2O 8.4 µl  
Gesamt 25 µl  
 
Table 6 real-time RT-PCR  master mix. 
 
Time [min] Temperature [°C] Cycles 
10:00 95 1 
0:30 95  
40 1:00 58-60 
0:30 72 
10:00 95 1 
0:30 55 
0:30 95 
 
Table 7 Real-time RT-PCR conditions 
 
All real time RT-PCR reactions were performed on the Stratagene Mx3005P with the MxPro 
software and the program “SYBR Green with Dissociation curve” to confirm the specificity 
of each primer. PCR products were seperated on a 3% agarose gel, to confirm that every 
primer yielded one specific product. All primer pairs were blasted with the NCBI primer blast 
tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and purchased from Metabion 
(Metabion GmbH, Martinsried, Germany). Tables 8 and 9 provide all primer sequences, 
annealing temperatures and product sizes. 
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Gen Bank 
Accession 
Name Forward Primer 5’3’ 
Reverse Primer 5’3’ 
product 
size 
annealing 
temp.[°C] 
NM_007482.3 Arginase GGTTCTGGGAGGCCTATCTT 
CACCTCCTCTGCTGTCTTCC 
127 58 
NM_011333.3 CCL2 TTAAAAACCTGGATCGGAACCAA 
GCATTAGCTTCAGATTTACGGGT 
121 60 
NM_009915.2 CCR2 TCCTTGGGAATGAGTAACTGTGT 
TGGAGAGATACCTTCGGAACTT 
142 60 
NM_009914.4 CCR3 CAGATACCTGGCTATCGTCCA 
GGCTCGAAGGGCAAACACA 
43 60 
NM_009892.2 Chitinase CCCTGGGTCTCGAGGAAGCCC 
GCAGCCTTGGAATGTCTTTCTCCAC 
113 58 
NM_011045 CX3CL1 CCAGAGCTGGCAATAACCTA 
GGCATACAGGGTACGATCTG 
193 58 
NM_009987 CX3CR1 GTGACATGAAGAGGGACCTG 
CCCTCGCTTGTGTAGTGAGT 
247 58 
NM_013556.2 HPRT GCTGACCTGCTGGATTACAT 
TTGGGGCTGTACTGCTTAAC 
242 58 
NM_010548.2 IL-10 CAGAGAAGCATGGCCCAGA 
TGCTCCACTGCCTTGCTCTTA 
 130 58 
NM_031167.5 IL-1RA TCCTGTTTAGCTCACCCATGG 
CCAGCAATGAGCTGGTTGTTT 
136 58 
NM_008361.3 IL-1β ACCCCAAAAGATGAAGGGCTG 
TACTGCCTGCCTGAAGCTCT 
112 58 
NM_031168.1 IL-6 TCTCTGCAAGAGACTTCC 
AGTAGGGAAGGCCGTGGTTGT 
90 58 
NM_008611.4 MMP 8 GGCCCTTCCTACCCAACGGT 
AGAGCCCAGTACTGTCTGCCTTT 
91 58 
NM_013599.2 MMP 9 ACGGGTATCCCTTCGACGGC 
AGTGGGGATCACGACGCCTTT 
131 58 
NM_011045 PCNA GGGTTGGTAGTTGTCGCTGT 
TCCAGCACCTTCTTCAGGAT 
172 58 
NM_013693.2 TNFα CATCTTCTCAAAATTCGAGTGACAA 
TGGGAGTAGACAAGGTACAACCC 
175 58 
NM_001025257.4 VEGFa GGCCTCCGAAACCATGAACTT 
TGGGACCACTTGGCATGGT 
87 58 
NM_001185164.1 VEGFb AGCCAGACAGCCCCAGGAT 
AGCAGCTTGTCACTTTCGCG 
176 58 
NM_009506.2 VEGFc ACCTCCATGTGTGTCCGTCT 
TTCAAACAACGTCTTGCTGAGG 
103 58 
NM_010810.4 MMP 7 AGCTTCCCCTTTGATGGGCCA 
GGAAGTTCACTCCTGCGTCCT 
130 58 
NM_001081117 Ki67 CTCCACGAACCTCAAAGAGA 
TGTGGATTCCTTCACACCTT 
164 58 
NM_019471.2 MMP 10 TGAGAAATGGACACTTGCACCCTC 
ACCGGCTCCATACAGGGATTGAAT 
199 58 
NM_008606.2 MMP 11 CTTCGCCAGGTACTGGCATGGTG 
TGGCCAAATTCATGAGCCGCC 
183 58 
NM_008607.2 MMP 13 AGCAGTTCCAAAGGCTACAACTTGT 
GGGTTGGGTCTTCATCGCCT 
199 58 
NM_008610.2 MMP 2 GTCCCGAGACCGCTATGTCCA 
ACACCTTGCCATCGTTGCGG 
126 58 
NM_010809.1 MMP 3 TCCCTCTATGGAACTCCCACAGCA 
GGAGTCCTGAGAGATTTGCGCCA 
185 58 
NM_010927.3 iNOS CACCAAGCTGAACTTGAGCG 
CCATAGGAAAAGACTGCACCG 
105 58 
Table 8 Murine real-time RT-PCR primers. 
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Gen Bank 
Accession 
Name Forward Primer 5’3’ 
Reverse Primer 5’3’ 
product 
size 
annealing 
temp.[°C] 
NM_002982.3 
 
CCL2 CAGCCAGATGCAATCAATGCC 
TGGAATCCTGAACCCACTTCT 
190 58 
NM_001123396 
 
CCR2 TGTCCACATCTCGTTCTCGGT 
CCGCTCTCGTTGGTATTTCTGA 
46 58 
NM_002996.3 
 
CX3CL1 CAAACGCGCAATCATCTTGG 
ATTTCGAGTTAGGGCAGCAG 
121 58 
NM_001171174.1 CX3CR1 ATATTGGGGACATCGTGGTCT 
TGGCAAAGATGACGGAGTAGA 
66 58 
NM_000194.2 HPRT TGACACTGGCAAAACAATGCA 
GGTCCTTTTCACCAGCAAGCT 
94 58 
 
Table 9 Human real-time RT-PCR primers 
3.1.9 Immunocytochemistry (ICC) 
LLC1 (20.000) or MΦ (50.000) cells were seeded on 8-well glass chamber slides (BD 
Biosciences)  and cultured for 24 h. LLC1 cells were stimulated with either control or co-
culture CM and incubated for another 24 h. MΦ were directly subjected to ICC. Cells were 
fixed in ice cold methanol/acetone (1:1) (Roth, Karlsruhe, Germany), washed and blocked 
with blocking buffer (5% BSA, 0.5 % serum, according to secondary antibody (AB), 0.2% 
Triton-X in PBS), and incubated over night with the primary AB. After washing and  
incubation with the secondary AB, the slides were incubated with DAPI (Dako, Glostrup, 
Denmark) for nuclear counterstaining and mounted with fluorescence mounting media 
(Dako). Pictures were taken with the same gain and exposure time dependent on the primary 
AB. Fluorescence pictures were taken with the Leica DM6000B equipped with the Image 
Analysis & Processing Software for Quantitative Microscopy Leica QWin (Leica 
Microsystems GmbH, Wetzlar, Germany). 
Antibody Species/reactivity Company,  
Catalogue-No. 
Antigen-
retrieval 
Dilution 
Alexa488® (2°) Goat anti-rat and 
Goat anti-rabbit 
Invitrogen 
A-11034; A-11006 
- 1:1000 
Alexa594® (2°) Goat anti-rat and 
goat anti-rabbit 
Invitrogen  
A-11012; A-11007 
- 1:900 
CCR2 Rabbit anti-mouse Abcam; ab32144 Citrate 
ProteinaseK 
1:100 
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Antibody Species/reactivity Company,  
Catalogue-No. 
Antigen-
retrieval 
Dilution 
CD11b Rat anti-mouse Millipore; MAB1387Z Trypsin 1:200 
CD68 Rat anti-mouse AbD Serotec; MCA1957 Citrate 1:200 
CX3CR1 Rabbit anti-mouse NOVUS; NBP1-76949 Citrate 1:100 
F4/80 Rat anti-mouse Abcam; ab6640 
 
Trypsin 
ProteinaseK 
1:100 
MoMa2 Rat anti-mouse AbD Serotec; 
MCA519G 
just ICC 1:200 
PCNA Rabbit anti mouse Santa Cruz 
Biotechnology; 
Sc7907 
Citrate 1:150 
 
Table 10 Antibodies 
3.1.10 Migration assay 
Chemotactic migration was quantified using a Boyden chamber transwell assay (8 µm pore 
size; uncoated filters; BD Biosciences). Either control (MΦ or LLC1 alone) or co-culture-CM 
(from 12 h and 24 h co-culture) was provided in the lower part of the chamber, LLC1 cells (4 
× 104) were introduced into the upper chamber and left to migrate for 8 h. Additional controls 
were performed with media containing 0%, 1% or 20% FCS. The cells were fixed with 
methanol (Roth, Germany) and stained with crystal violet (Sigma-Aldrich, USA) and 
migrated cells in fifteen randomly chosen fields per filter were counted. Images were taken 
with the Leica Dm6000B using 20× magnification. The migration assay was repeated with 3-
5 different co-cultures per MΦ genotype (WT, CCR2-/-, CX3CR1-/-), and each experiment was 
performed in triplicate. 
3.1.11 Proliferation assay 
Proliferation assays were performed with serum starved LLC1 cells exposed for 24 h to either 
control or co-culture-CM (12 h, 24 h).  After incubation for 20 h, BrdU (bromdesoxyuridin) 
was added and its incorporation was detected using an HRP-coupled antibody by measuring 
the absorption of the HRP-substrate at 370 nm, according to the manufacturer’s instructions 
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(Cell Proliferation ELISA, BrdU colorimetric, Roche,). Detection was performed with the 
Tecan infinite M200 Pro. 
3.1.12 ELISA (enzyme-linked immunosorbent assay) 
Mouse CCL2 and CX3CL1 levels were quantified in either control or co-culture-CM (12 h 
and 24 h) as well as in plasma levels of tumor-bearing WT, CCR2-/- and CX3CR1-/- mice with 
the Mouse CCL2/JE/MCP-1 Quantikine ELISA Kit and the Mouse CX3CL1/Fractalkine 
Quantikine ELISA Kit, respectively, according to the manufacturer’s instructions. Human 
CCL2 in control or co-culture CM (24 h) was measured with the Human CCL2/MCP-1 
Quantikine ELISA Kit (all R&D Systems). 
 The final colorimetric reaction was detected at 450 nm using the Tecan infinite M200 Pro 
and quantified using the Magellan V7.0 software (Tecan Group Ltd, Männedorf, Switzerland). 
3.1.13 Cytokine arrays 
Cytokine arrays (mouse cytokine antibody array, panel A, R&D Systems, Minnesota, USA) 
were performed to detect secreted mediators in either co-culture or control medium or plasma 
of tumor bearing mice. Samples of CM of LLC1, MΦ and co-culture or plasma of WT, 
CCR2-/- and CX3CR1-/- mice were incubated with the Panel A Detection Antibody Cocktail 
(Biotin-labeled). Nitrocellulose membranes spotted with capture antibodies against 40 
different cytokines, as well as positive and negative controls, were first blocked and 
subsequently incubated with the prepared samples. The AB-Cytokine-AB-coupling reaction 
was detected by adding a streptavidin-HRP solution followed by incubation with Chemi 
Reagent Mix.. The reactions were visualized with Amersham Hyperfilm ECL films (GE 
Healthcare Europe GmbH, Freiburg, Germany). Analysis and quantification was performed 
with the BioDoc Analyze Software from Biometra. 
3.2 Experimental procedures – in vivo 
3.2.1 Mouse lines 
Wildtype (WT) C57/Bl6 mice were obtained from Charles River GmbH, Sulzfeld, Germany. 
All knock out lines were obtained from The Jackson Laboratories, Maine, USA, and 
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maintained under pathogen-free conditions according to the European Communities 
recommendations for experimentation after approval by local authorities (animal proposal no. 
V54-19c20/15-B2/288). 
Additionally, the following gene-manipulated mice were used for experimental analysis: 
B6.129S4-Ccr2tm1Ifc 
The generation and characterization of this mouse line was previously described (Boring et 
al., 1997). Mice homozygous for the CCR2-deletion, show an abnormal leukocyte trafficking, 
especially impaired migration of myeloid-derived cells, e.g. MΦ. These mice also show a 
decreased acute inflammatory reaction with decreased MΦ infiltration. 
B6.129P-Cx3cr1tm1Litt 
These mice were created with an enhanced GFP-expressing target vector that disrupted exon 2 
of the coding region of the CX3CR1 gene. As a consequence, all CX3CR1-expressing cells 
exhibit green fluorescence. The mice display abnormal leukocyte-chemotaxis, in particular, 
the migration of monocytes and NK-cells is impaired. A more detailed description of the 
generation of this mouse strain was previously described (Jung et al., 2000). 
C57BL/6-Tg(Csf1r-EGFP-NGFR/FKBP1A/TNFRSF6)2Bck/J 
These transgenic mice carry an inducible Fas suicide/apoptotic gene driven by the mouse Csfr 
(macrophage colony stimulating factor receptor 1) promoter. The gene construct (containing 
an IRES sequence, human low affinity nerve growth factor receptor [∆LNGFR], two copies 
of the 12kDa human FK506 binding protein 1A [FKBP12], and the intracellular domain 
region of the Fas gene) was inserted immediately downstream of the enhanced Green 
Fluorescent Protein (EGFP) gene (Figure 7). The resulting transmembrane protein binds the 
dimerization drug AP20187 (ClonTech, Takara holdings Inc., Kyoto, Japan) and induces 
apoptosis in MΦ and MΦ-derived DCs, resulting in an MΦ-depleted mouse. Seven days after 
cessation of treatment, the MΦ and MΦ-derived Dc populations undergo regrowth. The 
generation and characterization of this mouse strain was previously described (Burnett et al., 
2004). These mice are referred to as MaFIA-(Macrophage Fas Induced Apoptosis)-mice. 
 
Figure 7 MaFIA Transgene 
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3.2.2 Genotyping 
B6.129S4-Ccr2tm1Ifc 
Following primer pairs detected CCR2-deletion: 
Primer 
 
Forward Primer 5’3’ 
Reverse Primer 5’3’ 
Band 
size 
 
Wildtype CCACAGAATCAAAGGAAATGG 
CCAATGTGATAGAGCCCTGTG 
424 bp 
Mutant CTTGGGTGGAGAGGCTATTC 
AGGTGAGATGACAGGAGATC 
280 bp 
 
Table 11 CCR2 Genotyping primer and band sizes; (1-4) homozygous CCR2-/- mice, (+) positive           
control , (+/-) heterozygous mouse, (wt) wildtype, (n) negative control. 
Sample preparation  PCR 
Reaction 
Component 
Volume 
[µl] 
Final 
Concentration 
 Temp [°C] Time [sec] Cycles 
ddH2O  4.75 -  95 120 1 
Buffer 12.5 1.00 X  95 15  
25 mM MgCl2  0.5 2.00 mM  59 15 35 
DMSO  1.25 0.20 mM  72 60  
each Primer  1.25 1.00 uM  72 120 1 
DNA 1.00 -  4 ∞ 1 
 
Table 12 CCR2 Genotyping RT-PCR conditions 
PCR for genotyping was carried out with the reagents (KAPA Genotyping HOT Start Kit, 
peqlab Biotechnologie GmbH, Erlangen, Germany) and conditions listed in table 11 and 12. 
 
B6.129P-Cx3cr1tm1Litt 
Following primer pairs detected CX3CR1-deletion: 
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Primer 
 
Forward Primer 5’3’ 
Reverse Primer 5’3’ 
Band 
size 
 
Wildtype GTCTTCACGTTCGGTCTGGT 
CCCAGACACTCGTTGTCCTT 
410 bp 
Mtant CTCCCCCTGAACCTGAAAC 
CCCAGACACTCGTTGTCCTT 
500 bp 
 
Table 13 CX3CR1 Genotyping primer and band sizes; (35, 36,38,39) homozygous CX3CR1-/- mice,    
(37,40) heterozygous mice, (+) positive control, (+/-) heterozygous control, (wt) wildtype, (n) negative 
control. 
PCR for genotyping was carried out with following reagents (KAPA Genotyping HOT start 
Kit, peqlab Biotechnologie GmbH, Erlangen, Germany) and conditions: 
Sample preparation  PCR 
Reaction 
Component 
Volume 
[µl] 
Final 
Concentration 
 Temp [°C] Time [sec] Cycles 
ddH2O  6 -  94 180 1 
Buffer 12.5 1.00 X  94 30  
25 mM MgCl2  0.5 2.00 mM  65 30 35 
DMSO  1.25 0.20 mM  72 60  
each Primer  1.25 1.00 uM  72 120 1 
DNA 1.00 -  4 ∞ 1 
 
Table 14 CX3CR1 Genotpying RT-PCR conditions. 
 
C57BL/6-Tg(Csf1r-EGFP-NGFR/FKBP1A/TNFRSF6)2Bck/J 
Following primer pairs detected MaFIA-transgene insertion: 
Primer 
Type 
Forward Primer 5’3’ 
Reverse Primer 5’3’ 
Band 
size 
 
Internal 
control 
CTAGGCCACAGAATTGAAAGATCT 
GTAGGTGGAAATTCTAGCATCATCC 
324 bp 
Mutant AAGTTCATCTGCACCACCG 
TCCTTGAAGAAGATGGTGCG 
173 bp 
 
Table 15 MaFIA Genotyping primer and band sizes, (wt) wildtype, (12-16) mice positive for MaFIA-
transgene, (+) positive control. 
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PCR for genotyping was carried out with following reagents (RED Taq Ready Mix. Sigma 
Aldrich, St. Louis, USA) and conditions: 
Sample preparation  RT-PCR 
Reaction 
Component  
Volume 
[µl] 
Final 
Concentration 
 Temp [°C] Time [sec] Cycles 
ddH2O  7.8 -  95 180 1 
Buffer  10 1.00 X  95 30  
each Primer  0.3 1.00 uM  60 30 35 
DNA 1.00 -  72 60  
 
   72 120 1 
 
   4 ∞ 1 
 
Table 16 MaFIA Genotyping RT-PCR conditions. 
3.2.3 MΦ -depletion with clodronate-liposomes or AP20187 
MΦ were depleted in vivo with either clodronate liposomes (CLs) or AP20187 in MaFIA-
mice. CLs (obtained from www.clodronateliposomes.org) are ingested by MΦ via 
endocytosis and after fusion with lysosomes in the cytoplasm of MΦ, clodronate is released 
and induces apoptosis via inhibition of the mitochondrial ADP/ATP translocase. CLs are 
unable to pass vascular barriers, e.g. after orotracheal aspiration, alveolar MΦ are depleted in 
the lung but not alveolar interstitial MΦ. The preparation and detailed analysis of tissue 
distribution has been previously described (van Rooijen and van Kesteren-Hendrikx, 2002). 
Control mice were treated with PBS Liposomes. 
AP20187 was dissolved in 100% ethanol in a concentration of 62.5 µg/µl as a stock solution. 
30 min prior to injection, the stock solution was diluted to 2.5 µg/µl with dilution buffer 
(1.7% Tween-20, 1% PEG-400 and 0.9% NaCl). Mice were balanced and injected at a dose of 
10 mg/kg bodyweight, and the final injection volume was adjusted to 100 µl using a dilution 
buffer. Control mice were peritoneally injected with 100 µl dissolvent without AP20187. 
For analysis of tumor growth in CL MΦ depleted- or in MaFIA mice, daily intraperitoneal 
pretreatment with either CL in WT-mice or AP20187 (ClonTech), respectively, was started 4 
days prior to LLC1 injection, followed by continuous intraperitoneal and intratumoral 
injections every 4th day. Experimental schemes are provided in the according results section. 
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3.2.4 Syngeneic subcutaneous model of lung cancer 
Primary tumor growth from LLC1 was monitored as described in (Savai et al., 2007). Briefly, 
1 × 106 LLC1 cells were subcutaneously injected (24g needle, 0.55 × 25 mm, Neolus, Terumo 
Europe, Leuven, Belgium) subcutaneously into C57BL/6 WT, or MΦ-depleted mice (CL or 
MaFIA). Tumor growth was measured every 4 days with digital calipers. At day 21 mice were 
sacrificed and tumor, lung, liver and spleen were balanced and analyzed for FACS, 
immunohistochemistry or molecular biology techniques.  
3.2.5 Syngeneic metastatic model of lung cancer (tumor relapse model) 
Primary tumor growth was initiated as described above in WT, CCR2-/-, CX3CR1-/- and CL 
treated mice. After 10 days, mice were intubated and anaesthetized using isoflurane 
anesthesia (Forane, Baxter, Deerfield, USA) with 4-5% to initiate and 2-3% to obtain 
anesthesia. Skin covering the subcutaneous (s.c) tumor was shaved and disinfected with 70% 
ethanol, Metamizol (200 mg/kg bodyweight) was subcutaneously injected for preoperative 
analgesia.   The s.c. tumor was extracted and the wound sewed (Vicryl*Plus Absorbable, RB-
1 plus, 17mm ½ c, Johnson&Johnson Intl., St-Stevens-Woluwe, Belgium). Postoperative 
analgesia was obtained using Metamizol (200 mg/kg bodyweight) in drinking water. All mice 
were intensively observed over a following period of 20-40 days. Tumor metastasis in the 
lung was evaluated by MRI (magnetic resonance imaging) on days 20 and 30. After the mice 
were sacrificed, according to humane endpoints (scoring sheet), the lungs (after perfusion), 
liver and spleen were extracted and photographed. All macroscopic nodules (≥ 1 mm) were 
counted and measured with digital calipers. All organs were fixed in 4% PFA for 
immunohistochemistry. 
3.2.6 Tumor digestion for FACS analysis 
To prepare subcutaneous tumors for flow cytometric analysis of infiltrating MΦ, extracted 
tumors were placed in 35 × 10 mm petri dishes (Greiner Bio-one, Frickenhausen, Germany) 
and cut in small cubes (< 1 mm3) with a scalpel. Two ml of a digestion solution of 0.2 mg/ml 
collagenase-D (Roche Diagnostics, Mannheim, Germany), 1 mg/ml pronase (Roche 
Diagnostics, Mannheim, Germany) and 2 µl DNAseI (400 U/ml, Promega, Madison, USA) 
were added, and samples were incubated for 40 min at 37°C on a shaker. The digested tissue 
was resuspended in 10 ml PBS with 10% FCS to stop the digestion reaction and centrifuged 
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for 5 min with 1600 rpm. The pellet was washed with PBS and passed through a 40 µm cell 
strainer (BD Biosciences) and cells were counted. The cell suspension was then centrifuged, 
resupended in 1 ml ice-cold 1% PFA per 106 cells, and fixed for 15 min on ice. After 
centrifugation, cells were prepared in FACS buffer (PBS-/-, 0.15% EDTA, 10% FCS, pH 7.2) 
for staining and flow cytometry (see point 3.1.7). EDTA solution was purchased from 
Biochrom AG, Berlin, Germany.  
3.2.7 Histology 
3.2.7.1 Hematoxylin and eosin staining 
Sections (3 µm) from paraffin embedded tissues were first rehydrated with a continuous 
xylol-ethanol 99%- ethanol 90%- ethanol 70% row. After washing in distilled H2O, slides 
were incubated in fresh hematoxylin (Merck, Darmstadt, Germany) for 15 min and washed in 
distilled H2O until was removed from the tissue. Next, the slides were incubated with freshly 
prepared eosin (Merck, Darmstadt, Germany) for 1 min. The slides were washed in ddH2O 
again, dehydrated with ascending ethanol concentrations (70%, 90%, 99%) and finally 
mounted with Pertex Mounting Media (Leica Biosystems, Wetzlar, Germany. Pictures of 
whole H&E stained sections were acquired with the microscope SteREO Discovery. V8 
microscope, equipped with the software AxioVision4.7.1 software. (Carl Zeiss AG, 
Oberkochen, Germany) 
3.2.7.2 Immunohistochemistry (IHC) 
For IHC staining, 3 µm sections were rehydrated and antigen retrieval was achieved with 
citrate buffer/heat, trypsin- or proteinase-K treatement as indicated in  
Table 10. After blocking (5% BSA, 0.2% Triton-X, 0.5 % serum according to secondary AB), 
sections were incubated with the following primary antibodies: F4/80, CD11b or PCNA. 
Indirect immunofluorescence was conducted by incubation with Alexa488- or Alexa594-
conjugated secondary antibodies (Invitrogen). Nuclei were counterstained with DAPI, and 
sections were mounted with fluorescent mounting media (Dako). All fluorescence images 
were acquired with the same exposure time in 40× and 20× magnification with a Leica 
DM6000B microscope equipped with the Image Analysis & Processing Software for 
Quantitative Microscopy Leica QWin (Leica Microsystems GmbH, Wetzlar, Germany). 
Positive cells were quantified from 15 randomly taken pictures per slide and calculation of the 
positive/total cell ratio. 
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3.2.8 µ-computed tomography (µCT) 
3.2.8.1 Animal preparation 
Animals were euthanized with a fatal dose of inhaled isoflurane and fixed in supine position. 
After thoracotomy, the left ventricle was cannulated with a 24 G needle and the right atrium 
was incised. 10 ml of heparinized saline were injected until the effluent from the right 
ventricle was free from blood. The injection rate was 0.3 ml/s, mimicking a physiological 
minute volume of 18 ml. Next, 10 ml of Microfil (Microfil® MV-122; Flow Tech, Carver, 
MA, USA), a plumbiferous intravasal polymerizing contrast agent, was injected at the same 
injection rate. Tumors were excised 45 min after injection with a sufficient intravasal 
hardening of the contrast agent and fixed in neutral buffered formaline. 
3.2.8.2 µ-CT imaging 
Tumors were wrapped in parafilm to prevent dehydration and scanned in a micro-computed 
tomograph (micro-CT; SkyScan (SkyScan1072_80 kV, Kontich, Belgium). The system is 
equipped with a microfocus tube (20-80 kV, 0-100 µA) reaching a minimum spot size of 8 
µm at 8 W generating X-rays in cone-beam geometry and was described in detail 
(Langheinrich et al., 2004). The detector consists of a 1024 × 1024 pixel matrix with a 12 bit 
digital CCD high-resolution camera and digital frame-grabber. For this study, tube voltage 
was chosen at 75 kV with a beam hardening filter of 0.5 mm aluminium. To obtain an optimal 
resolution, geometric magnification, i.e. spatial resolution, was chosen individually depending 
on the tumor size. Side length of the resulting isotropic pixels was between 14 and 18 µm. 
Cross sectional images were reconstructed using a modified Feldkamp cone-beam 
reconstruction algorithm with a grey scale resolution of 8 bit (0-255). 
3.2.8.3 nano-CT imaging 
Cubic specimens of 5 mm side length were excised from well-perfused tumor areas as 
predetermined from the previous acquired micro-CT data sets. Specimens were stored in 
parafilm and scanned using nano-computed tomography (SkyScan 2011, Kontich, Belgium). 
The system is equipped with an open pumped type X-ray source, a LaB6 cathode, and a 
transmission anode consisting of a tungsten coated beryllium window. Superior edge 
sharpness is reached by a high focussed X-ray spot of 300 nm side length. Tube voltage was 
70 kVp. The system was previously described in detail (Langheinrich et al., 2010). Cross 
sectional images were reconstructed with a modified Feldkamp cone-beam reconstruction 
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algorithm. Image resolution of the cross sectional images was 6 µm isotropic voxel side 
length with the same grey scale resolution of 8 bit.  
3.2.8.4 Quantification 
1) Micro-CT data sets 
Measurements of tumor size and whole tumor vascularization were performed using the 
Analyze 10.0 software package (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN, 
USA). Thresholding for object identification (air + wax vs. tumor tissue vs. vascularization) 
was adapted to the grey level of the compartments and carried out semi-automated. Tumor 
volume and vascular volume were determined. Vascular volume fraction (VVF) was 
measured according to the following: 
VVF (%) = 3D CAV/ 3D TV × 100 %;  
with 3D_CAV (total contrast agent volume) representing the sum of all voxels tagged as 
contrast agent and 3D_TV (tumour volume) representing the volume of the entire specimen.  
2) Nano-CT data sets: 
Vascular morphometry was evaluated using the CTAn-Software package (SkyScan, Kontich, 
Belgium). Morphometric parameters were determined after binarization using an adaptive 
method for a more precise segmentation of vessels with suppression of typical nano-CT 
artifacts. The following parameters were determined for binarized 3D data sets: Vascular 
volume fraction (VVF), mean vascular thickness (ST.Th), mean vascular separation (Sr.Sp) 
and structure linear density (Sr.Li.Dn). Mean vascular thickness and mean vascular separation 
are image editing algorithms which identify the centreline of a vessel or the intervascular 
space (tissue) and measure the radius of the described structure by placing virtual spheres 
along the centreline which fit into the depicted structure. Structure linaer density describes the 
number of traversals of vascular structures along any linear distance in the volume by 
measuring the inverse of the mean centre line distances. 
3.2.9 Magnetic resonance imaging (MRI) 
MRI measurements were performed on a 7.0 T Bruker Pharmascan equipped with a 300mT/m 
gradient system and using a custom-built circularly polarized birdcage resonator. The 
frequency for the 1H isotope is 300.33 MHz. Localizer images were acquired by spin echo 
sequence (repetition time, TR = 205 ms; echo time, TE = 10 ms; slice thickness = 5 mm) with 
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three orthogonal slices (axial, coronal and sagittal) for rough positioning. RARE-(Rapid 
Acquisition with Relaxation Enhancement) sequences in axial, coronal and sagitall orientation 
(TR = 2500 ms, TE = 36.7 ms and slice thickness = 1 mm) were used to verify a strictly 
symmetric positioning of the mouse. For reducing inhomogeneity in the region of the lung a 
correction of the shim on the basis of a Bo field map was executed. For lung imaging we 
employed the respiratory gated UTE 3D- (Ultra-Short-Echo Time) sequence (TE = 20 µs; TR 
= 8.0 ms; FOV = 2.5 × 2.7 ×5.0 cm3; matrix = 128×128×128; slice thickness = 0.39 mm) for 
WT, PBS-treated and CCR2-/- mice or the respiratory gated ZTE- (Zero Echo Time) sequence 
(TE = 0 µs; TR = 4,0  ms; FOV = 3,0x3,0x4,0 cm2; matrix = 256x256; slice thickness = 0,16 
mm) for CL-depleted and CX3CR1-/- mice. Mice were measured under volatile isoflurane (1.5 
– 2.0 % in oxygen and air with a flow rate of 1.0 L/min) anesthesia; the body temperature was 
maintained at 37°C by a thermostatically regulated water flow system during the entire 
imaging protocol.  
3.3 Data analysis 
Statistical analyses were performed with the GraphPad Prism 5 Software following the 
guidelines found in GraphPad Prism. One-way ANOVA followed by Tukey’s posttest was 
used to compare the means of more than two independent groups; two independent groups 
were compared with the Student’s t test. All sample sizes were tested for Gaussian 
distribution and subjected to Grubbs’ outlier test.  Data are expressed mean ± SEM; statistical 
significance was set at p ≤ 0.05. Significance level is noted as follows: * p ≤ 0.05, ** p ≤ 
0.01, ***p ≤ 0.001. 
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4 Results 
4.1 Systemic depletion of MΦ in mice 
4.1.1 CL mediated depletion of MΦ in primary tumor growth 
MΦ are involved in various processes in tumor progression and metastasis                    
(Pollard, 2004). However, long-term studies with a systemic depletion of MΦ are lacking. We 
depleted MΦ in C57/Bl6 mice bearing s.c. LLC1 tumors with CL, which specifically kill 
phagocytosing MΦ after engulfment of liposomes and accumulation of clodronate in their 
cytoplasm (Van Rooijen and Sanders, 1994). To ensure a complete MΦ depletion during 
tumor initiation and formation, we started MΦ depletion 4 successive days prior to LLC1 
injection. Since the MΦ population starts to regenerate within seven days, we injected 
clodronate or PBS liposomes i.p., respectively, every 4th day to maintain the systemic 
depletion (Figure 8A). To specifically target the TAM, we additionally injected CL directly in 
the tumor. 
 The chronic systemic MΦ depletion resulted in the expected significantly inhibited primary 
tumor growth from day 16 (1158.86 ± 143.13 mm3 in the control group vs. 551.00 ± 94.784 
mm3 in CL-treated group) and was finally reduced about 56% from a volume of 3284.447 ± 
176.48 mm3 to 1452.55 ± 168.767 mm3 compared to control (PBS-Liposomes). The weight of 
extracted tumors (day 21) was significantly decreased from 4.00 ± 0.4359 g to 1.667 ± 0.2140 
g in the CL-treated group. Since the measurement with digital calipers also measures 
additionally skin and hair of the mice, we confirmed the significant difference in the tumor 
volume between the groups with a more exact µCT measurement of the extracted tumors, 
although the occurring error with digital calipers can be assumed to be a systemic error 
(Figure 8B-E). 
 Surprisingly, both groups showed no difference in gain of body weight. Whereas the control 
group still gained 4.23 ± 0.189 g in average, the CL-treated mice gain just 1.87 ± 0.491 g. 
Since the gain of weight includes also the weight of the growing tumor, these values don’t 
represent a normal gain of weight due to growth. This might be a hint, that an unspecific 
targeting of the entire MΦ-population can decrease the primary tumor growth, but is 
eventually not beneficial for the mice (Figure 8F). 
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Figure 8 CL-mediated MΦ depletion inhibits primary tumor growth. (A) Schematic of the experimental 
procedure (, injections) (B) Representative pictures of extracted tumors (C) Volume (measured with digital 
calipers at the indicated time points) and (D) Weight of tumors from CL-treated or control mice (E) Tumor 
volume as assessed with µCT (F) Mice bodyweight. All data represents mean ± SEM, n = 10, * p≤0.05, 
**p≤0.01, ***p≤0.001. 
The number of PCNA+ cells (positively stained cells per total cells) in tumor tissue was 
decreased from 82.57 ± 4.705 in the control group to 18.54 ± 12.03 in CL-treated mice, 
supporting the finding of decreased tumor growth in CL- treated mice        (Figure 9A-B). 
Staining for F4/80+ positive cells revealed a decrease of MΦ within the tumor 
microenvironment, which was confirmed and quantified with flow cytometric analysis. 
Interestingly, the flow cytometry results showed an approximate 56% reduction of MΦ 
accumulation, similar to the changes in primary tumor volume, indicating the direct 
involvement of MΦ in primary tumor growth (Figure 9C-D).  
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Figure 9 CL-treatment decreases PCNA+ cells and macrophages in the tumor microenvironment. (A) 
Immunohistochemistry for and (B) Quantification of PCNA+ in s.c. tumor tissue from CL-treated mice and 
controls (C) Immunohistochemistry for F4/80+ cells (D) Flow cytometric analysis of Macrophage-accumulation 
in s.c. tumor tissue. White arrow indicates positive cells. All data represent mean ± SEM, n = 6-10, **p≤0.01. 
To further examine the consequences of MΦ depletion on the tumor stroma, tumor tissue 
lysate was screened for different MΦ polarization markers and the expression of chemokine 
receptors. Levels of the M1-phenotype marker iNOS was increased in the tumor tissue, 
whereas the M2-marker arginase levels were decreased. The M2-marker chitinase showed no 
significant change (Figure 10A). Moreover, the mRNA levels of the chemokine receptors 
CCR2 and CX3CR1 were significantly decreased in the CL-treated group: CCR2 was 
decreased by 2.071±0.4836 ∆Ct and CX3CR1 by 1.869±0.2360 ∆Ct in tumor tissue of the 
CLgroup, revealing an involvement of a CCR2+ cell population in tumor progression. Since 
CCR2 is typically expressed on monocytes and MΦ and the CX3CR1 is expressed on all 
leukocytes and due to this also on MΦ, this important CCR2+CX3CR1+ cell population can 
be, but not necessarily have to be MΦ. Additionally the chemokine receptor CCR3, mainly 
responsible for eosinophil granulocyte chemotaxis (Kampen et al., 2000) was not changed 
(Figure 10B).  
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To examine further consequences on the entire tumor microenvironment after MΦ depletion 
tumor tissue lysates were screened for mRNA expression of secreted MMPs and VEGFs, 
since these two groups can represent tissue remodeling and induced angiogenesis and MΦ are 
a concise source for these enzymes and growth factors (Goetzl et al., 1996; Lin and Pollard, 
2004). Two members of VEGF group were decreased, with only VEGFc showing a 
significant decrease and VEGFb showing a trend towards decrease (Figure 10C). VEGFc is 
important for lymph angiogenesis and importantly, like VEGFa binds to VEGFR-2 (Flk1), 
which is the main receptor responsible for VEGF-mediated actions such as endothelial cell 
migration and angiogenesis. Furthermore, VEGFc was recently described to be the main 
angiogenetic factor in cancer (Carroll et al., 2013; Terme et al., 2013). 
 
Figure 10 Changed mRNA expression within a MΦ-depleted tumor microenvironment. (A) Relative 
mRNA-expression levels of MΦ-polarization marker (B) Chemokine-receptors (C) VEGFs (D) Gelatinases (E) 
Stromelysins and (F) Collagenases. All data represent mean ± SEM, n = 6, *p≤0.05, **p≤0.01, *** p≤0.001. 
We focused on the secreted isoforms of MMPs, as their involvement is already well described 
in tumor progression and found several MMPs were decreased in the CL-treated tumor 
tissues. In particular, level of the subgroup of stromelysins (MMP-3, -10 and -11) were 
entirely, significantly less expressed. Further less expressed are the gelatinase MMP-9, with 
type IV collagen as main substrate and the collagenase MMP-13, which can degrade triple-
helical collagen as well (Figure 10D-F).  
Considering these marked changes in tumor growth and the microenvironmental composition 
including MΦ accumulation, MMP, VEGF and chemokine-receptor expression one possible 
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underlying mechanism of MΦ contribution to cancer growth could be alterations of the 
vasculature. The total vessel supply of s.c. tumors was quantified and visualized with a µCT 
and nanoCT. While there was no significant change but a clear difference by trend in the total 
volume of the macro-vasculature between the groups as assessed with the µCT, there were 
highly irregular, leaky vessels in the CL-group that are inefficient to provide the tumor with 
nutrition (Figure 11A-B). Importantly, there is a significant decrease in the important 
nurturing microvasculature as revealed with the nanoCT. Moreover, the structure linear 
density, a value representing the vessel number on a virtual 1 cm line, is also significantly 
decreased in the CL-treated group (Figure 11C).  
 
Figure 11 CL-mediated macrophage depletion results in alterations of macro- and microvasculature. (A) 
Vessel volume as assessed with µCT (B) Representative 3D-pictures of the microvasculatures evaluated with 
nano-CT (C) Vessel density and (D) Volume quantified with nanoCT (E) Vessel fractions according to theis 
diameter. All data represents mean ± SEM, n = 6, * p≤0.05, ** p≤0.01, * p≤0.001. 
Analysis of the different vessel fractions according to their vessel diameter, revealed a major 
difference in vessels of 0.028 - 0.050 µm size (Figure 11E). These crucial findings highlight 
the nano-CT as a highly accurate and more powerful tool than µCT, especially for analysis of 
neoangiogenesis in solid tumors. Taken together, these findings underline the generation of a 
Results 
 
51 
 
malnourished tumor-environment that lost its full capacity to grow due to MΦ-depletion and 
subsequent tumor microenvironmental changes.  
4.1.2 CL mediated depletion of MΦ in metastasis formation 
Since MΦ-depletion is affects the entire tumor microenvironment and especially ECM 
remodeling enzymes and vascularization, a significant impact of MΦ on metastasis formation 
was expected.  MΦ involvement in lung metastasis formation was examined using a new 
model, where the s.c. tumor was removed after ten days, which provokes metastasis, in the 
case of LLC1 primary to the lung. During the progression of the metastatic process, all 
animals were screened twice with an MRI (Figure 12A). The endpoint was defined according 
to the humane endpoint guidelines, which suggests the scarification of an animal that fails to 
pass a score sheet with defined point regarding outlook and behavior.  
The number of metastatic nodules in the lung of CL-treated mice was markedly decreased. 
Overall, the number of macroscopic metastases, detectable with the naked eye on the surface 
of the extracted lung, was approximately seven fold higher in the control group. These results 
were confirmed in H&E stained sections, where the number of detected nodules decreased 
from 10.25 ± 2.658 in the control group to 2.571 ± 0.8411 in the CL-treated group. 
Additionally, the MRI evaluation of metastatic tumor formation in the lung confirms these 
findings (Figure 12B-D). Furthermore, additional liver-metastases were observed in several 
control-animals but never in CL-treated animals. Due to the reduced lung metastasis, survival 
of mice in the CL-group was slightly, but significantly longer (Figure12E). This result 
confirms the observation in primary tumor growth (4.1.1), that a general systemic MΦ 
depletion influences tumor growth and metastasis, but may not be beneficial for the mice.  In 
line with that, MΦ accumulated less in the metastatic tumor microenvironment (Figure 12F-
G). 
 Due to the less vascularized primary tumors and lower availability of basement membrane 
and ECM down breaking enzymes like MMPs and VEGFs, the extravasation of tumor cells 
might be impaired and this results in a strongly impaired formation of metastatic nodules. 
Additionally, the MΦ in the metastatic nodule are less as well, so the same effect as in the 
primary tumor microenvironment can be assumed:  a reduced vascularization and with this a 
malnutrition of the tumor nodules and impaired growth. 
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Figure 12 CL-mediated MΦ depletion attenuates lung metastasis in vivo. (A) Schematic of  the experimental 
procedure (B) Representative pictures of metastatic lungs of CL-treated and control mice; from left to right: 
photograph of whole lung ex-vivo, MRI of lung in vivo and H&E staining of lung sections (C) macroscopic 
nodules on extracted lung and (D) in H&E stainings (E) Survival curve expressed as a percentage of total mouse 
number (F) Representative pictures of IHC-sections stained for F4/80 in tumor bearing and healthy lungs and 
(G) Quantification of F4/80+-cells compared to total cells. White arrows indicate positive cells. All data 
represents mean ± SEM; n = 6-10; * p≤0.05, ** p≤0.01, *** p≤0.001 
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4.1.3 MΦ depletion in the MaFIA mouse model 
The effects of MΦ depletion on primary tumor growth described in Section 4.1.1 were 
confirmed with a second, mechanistically different model of MΦ depletion in vivo, the 
MaFIA (Macrophage Fas induced apoptosis) mouse. In these mice, the c-fms promoter 
controls the expression of a suicide gene, which transcribes for a fusion protein of the 
cytoplasmic Fas-domain and the FK506-binding protein and administration of the chemical 
compound AP20187 causes dimerization of the suicide protein and results in Fas-mediated 
apoptosis of c-fms-expressing cells, mainly MΦ and Monocytes  (Burnett et al., 2006) (Figure 
13A). Importantly, the c-fms promoter is usually controlling the transcription of CSFR, the 
receptor for M-CSF. Recent data suggests, that M-CSF is a M2-polarizing cytokine, which 
implies that CSFR-expressing cells are most probably M2-polarized MΦ (Fleetwood et al., 
2009). So in this model, a more specific targeting of M2-MΦ and with this more benefit for 
the mice is expected. 
 
Figure 13 Primary tumor growth is inhibited in vivo in MΦ-depleted MaFIA Mice. (A) Schematic of the 
principle and experimental procedure (B) Representative pictures of extracted tumors (C) Tumor volume 
(measured with digital calipers on indicated time points) and (D) Tumor weight. (E) Mice bodyweight. All data 
represents mean ± SEM; n = 6-10; * p≤0.05, ** p≤0.01, *** p≤0.001, compared to control. 
Results 
 
54 
 
Indeed, the observed decrease of primary tumor growth was more pronounced with an earlier 
significance as soon as day 12 compared to the CL-depleted model. These findings were 
supported by a decrease of primary tumor volume and weight. In contrast to the CL-depleted 
model, the MaFIA-mice gained weight under the treatment, compared to controls          
(Figure 13B-E). 
Moreover, IHC analysis of sections from these s.c. revealed a reduced number of PCNA+ cells 
in the tumor from MaFIA mice, as an index of proliferation (Figure 14A-B). To quantify MΦ 
accumulation, first, tumor sections were stained for F4/80+ cells and second, digested tumors 
were analyzed with flow cytometry. In line with a stronger inhibition of tumor growth 
compared to the CL-depleted mice, more MΦ were depleted (approximately 91.9%) in the 
tumor microenvironment. To verify the systemic depletion, total intraperitoneal cells were 
isolated and analyzed with flow cytometry, and MΦ were decreased over 90%. Taken these 
both results together, a successful systemic long-term depletion of MΦ can be assumed         
(Figure 14C-E). 
 
Figure 14 Ap20187-treated MaFIA mice displays fewer PCNA+ cells and MΦ in the tumor 
microenvironment. (A) Immunohistochemistry for PCNA and (B) Quantification (C) Immunohistochemistry 
for F4/80+ cells (D) Flow cytometric analysis of MΦ accumulation in s.c. tumor tissue and (E) in the peritoneal 
cave. White arrows indicate positive cells. All data represent mean ± SEM, n = 6-10, * p≤0.05, ** p≤0.01, *** 
p≤0.001. 
Interestingly, the MΦ depletion of over 90% is accompanied by a very significant decrease of 
M2-markers in the tumor microenvironment with a simultaneous increase of M1-markers, 
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indicating that MaFIA mediated MΦ-depletion shifts the balance from M2- MΦ to tumor-
fighting M1-MΦ, which may provide a basis for the impressive tumor decrease (Figure 15A). 
The gain of weight and strong shift from M1 to M2 markers show that a more specific M2-
targeting via the M-CSF receptor, like in the MaFIA mice, is more beneficial for cancer-
bearing mice compared to a general depletion with CL.  At the same time, we were unable to 
detect the membrane expressed chemokine receptor CCR2 in the microenvironment. 
Additionally CX3CR1 expression was strongly decreased in the tumor stroma (Figure 15B). 
These findings strongly support the involvement of chemokine receptors in tumor 
development and progression. 
 
Figure 15 Phenotype marker and chemokine-receptor expression in the tumor microenvironment of 
MaFIA-mice. (A) Relative mRNA levels of M1- and M2-marker (B) relative mRNA-levels of chemokine 
receptors. All data represent mean ± SEM, n=6, * p≤0.05, ** p≤0.01, *** p≤0.001. 
4.2 In vitro co-culture of bone-marrow derived WT MΦ with murine lung 
adenocarcinoma cells (LLC1) 
4.2.1 Characterization of bone-marrow derived macrophages (BM- MΦ) 
After isolation and 10 days of culture in the presence of rmM-CSF, MΦ were subjected to 
ICC, to confirm the expression of common MΦ-marker like F4/80 and MoMa1 (Figure 16A). 
To verify the purity of the isolated MΦ against granulocyte or DC contamination, MΦ were 
analyzed with flow cytometry for the markers CD45, F4/80, CD11c, CD11b and GR-1 before 
experimental use. The purity of the isolation process was over 97% in all experiments   
(Figure 16B). 
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Figure 16 MΦ -marker expression and purity after generation of BM-MΦ. (A) Immunocytochemistry for 
F4/80 (left) and MoMa1 (right) (B) Flow cytometric analysis of bone marrow derived MΦ. 
4.2.2 Effect of co-culture on MΦ polarization 
MΦ can adopt different phenotypes, which are defined by functionality and expression 
patterns of intracellular markers as well as cytokine secretion patterns and TAMs are known 
to display a M2-phenotype (Hamilton, 2008; Mantovani et al., 2002), but the exact underlying 
mechanisms of this polarization-phenomena remain unclear. To test, if co-culture with cancer 
cells (LLC1) alone can induce an M2-phenotype, control and co-cultured MΦ were screened 
for typical M1markers (iNOS, IL-1β, IL-6 and TNFα) and M2-markers (arginase, chitinase, 
IL-10 and IL-1RA) and relative mRNA expression of these markers revealed that MΦ 
polarize into M2-MΦ after co-culture, with a significant reduction of the M1-marker iNOS 
and TNFα (Figure 17A) and a strongly significant upregulation of all screened M2-markers, 
such as arginase, chitinase, IL-10 and IL-1RA (Figure 17B).  
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Figure 17 MΦ polarization after co-culture with LLC1. (A) relative mRNA-levels of M1-polarization 
markers iNOS, IL-1β, IL-6, TNFα and (B) of M2-polarization marker arginase, chitinase, IL-10 and IL-1RA. All 
data represent mean ± SEM, n=6, * p≤0.05, ** p≤0.01, *** p≤0.001. 
4.2.3 Characterization of the cytokine profile in co-culture supernatants 
To gain an overview of the differentially secreted cytokines of LLC1 and MΦ after co-culture, 
an antibody-based cytokine-array for 40 different cytokines was performed using CM from 
co-culture-CM or LLC1 and MΦ CM alone (Figure 18). The cytokine array coordinates and 
entire list of cytokines are listed in the table in the appendix. 
Among the 36 cytokines, 19 were either higher or newly secreted in the co-culture CM. 
Interestingly, we found already 7 cytokines constitutively secreted by LLC1 alone.  Figure 19 
lists the strongest regulated or most abundant secreted cytokines.  Notably, LLC1 appear to 
secrete abundant amounts of the MΦ and MC attracting CCL2 and the mitogen and    
neutrophil attracting CXCL1, compared to other cytokines. Various cytokines such as IL-
1RA, IL-23, CCL5, CCL12, CXCL10 and MIP-2 are constitutively secreted by M-CSF-
generated MΦ and are therefore found on a similar level in co-cultured CM. 
Although the cytokine array has a maximum detection capacity of approximately 6000 
arbitrary units, as seen with the positive control, the mentioned cytokines still may be 
expressed higher in co-cultured CM, but the difference would not be detectable with the 
cytokine array. Cytokines that were secreted at significantly higher levels in the co-cultured 
CM include IL-1α, IL-23, M-CSF and TNFα, and those only secreted in the co-culture CM 
include IL-6, IL-10, CCL1, MIP-1α, MIP-1β, G-CSF and siCAM-1. Notably,                 
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Figure 18 Cytokine-Array Visualization of antibody spotted membranes after incubation with different CM 
and time points as indicated. CCL1 C-C motif chemokine 1; G-CSF granulocyte-colony stimulating factor; IL-6 
interleukin-6; IL-10 interleukin-10; MIP-1α macrophage inflammatory protein-1 alpha; MIP-1β macrophage 
inflammatory protein-1 beta 
eotaxin, the ligand for CCR3 was not detectable in any setting. CCR3 levels were also 
unchanged in MΦ-depleted tumor microenvironments (Figure 19). 
The remarkable effect of MΦ depletion on tumor growth and metastasis, reduction in 
expression of chemokine receptors CCR2 and CX3CR1 in the tumor microenvironment and 
the extremely high levels of the MΦ chemoattractant CCL2 detected with the cytokine array 
suggests a chemokine mediated interplay between lung cancer cells and MΦ. 
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Figure 19 Co-culture-regulated and constitutively secreted cytokines All data represent mean ± SEM, * 
p≤0.05, ** p≤0.01, *** p≤0.001. * compares LLC1-CM vs. co-culture-CM, # compares LLC1-CM vs. MΦ-CM. 
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Thus, first the CCL2 secretion observed in the co-cultured CM was assigned to one cell type. 
Relative mRNA levels of CCL2 in control and co-cultured LLC1 clearly show LLC1 as a 
major source of CCL2. CCL2 transcription was significantly upregulated in LLC1 after co-
culture at every time point (Figure 20A). As the cytokine array can only detect relative levels, 
CCL2 secretion was further confirmed and quantified via ELISA (Figure 20B).  
Since not only CCR2 was significantly less expressed in the tumor microenvironment, but 
also CX3CR1 (Figure 15B) the secretion of CX3CL1 ligands was investigated. Results were 
similar to those of CCL2-secretion. CX3CL1 mRNA level was significantly upregulated in 
co-cultured LLC1 (Figure 20C) and CX3CL1 was significantly secreted at higher levels in 
co-culture CM (Figure 20D). 
 
 
Figure 20 CCL2 and CX3CL1-secretion of LLC1. (A) Relative CCL2 mRNA expression in control (white 
bars) or co-cultured LLC1 (black bars) (B) CCL2 secretion (ELISA) (C) relative CX3CL1 mRNA expression in 
control or co-cultured LLC1 (D) CX3CL1-secretion (ELISA) All data represent mean ± SEM, n=6, * p≤0.05, ** 
p≤0.01, *** p≤0.001. 
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4.2.4 Expression profile of chemokine receptors in LLC1 
Since LLC1 abundantly secret chemotactic working peptides like CCL2 and CX3CL1, they 
also might express the according receptors, CCR2 and CX3CR1. Interestingly, a screen of 
LLC1 revealed weak basal expression of CX3CR1, but not CCR2 or CCR3.  
 
Figure 21 CCR2 and CX3CR1 expression on LLC1. (A) relative mRNA expression of CCR2, (B) CX3CR1 
and (C) CCR3 in directly co-cultured LLC1. (D) CCR2 or CX3CR1 expression on LLC1 after stimulation with 
the indicated conditioned media from indicated co-culture time points (E) relative mRNA expression of CCR2 
and (F) CX3CR1 on CM stimulated LLC1 (G) relative mRNA expression of CCR2 or (H) CX3CR1 in LLC1 
after co-culture with MΦ of different phenotype. All data represent mean ± SEM, n=6, * p≤0.05, ** p≤0.01,   
*** p≤0.001. * compares LLC1 vs. co-cultured LLC1, § compares  MΦ-CM stimulated LLC1 vs. co-cultured 
LLC1 
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More importantly, CCR2 and CX3CR1 receptors were significantly upregulated in LLC1 
after co-culture with MΦ (Figure 21A-C).  
To analyze if the CCR2 onset or CX3CR1 upregulation is only dependent on MΦ secreted 
factors or the result of the communication of both cell types, fresh LLC1 were stimulated with 
CM derived from co-cultures. This experiment confirmed that the chemokine-receptor 
upregulation is dependent on the exchange of secreted factors between LLC1 and MΦ, since 
the upregulation is absent after stimulation with only MΦ-CM, but present after stimulation 
with co-culture CM (Figure 21D-F). 
To test if the described chemokine-receptor upregulation by LLC1 might be dependent on the 
MΦ-phenotype, LLC1 were co-cultured with either M1 or M2-MΦ. Importantly, we  
observed a significantly stronger upregulation of CCR2 after co-culture with M2-MΦ, 
whereas the CX3CR1 upregulation was overall independent of the MΦ phenotype        
(Figure 21G-H).  
Taken together, these results suggest an active attraction of MΦ by LLC1 and a subsequent 
biomimicking of MΦ receptor expression by LLC1 after interaction with MΦ. This loop is 
enforced by M2-polarization of MΦ. 
4.2.5 Expression profile of MMPs and VEGFs on LLC1 and BM-MΦ 
Levels of VEGFs and several MMPs were decreased in the tumor microenvironment of MΦ-
depleted mice. To study if, inversely, co-culture with MΦ can upregulate these effector 
molecules, mRNA from control and co-cultured LLC1 samples was screened for VEGF 
expression, and MΦ mRNA was screened for MMP expression, since MΦ are the typical 
source of MMPs.  VEGFa and VEGFc, but not VEGFb were significantly upregulated after 
co-culture with MΦ (Figure 22A).  
Furthermore, the entire group of stromelysins (MMP-3, -10 and -11) was upregulated in MΦ 
after co-culture, which is well in line with our in vivo observation, where this group of MMPs 
was entirely downregulated in MΦ-depleted mice. In addition MMP-8, -9 and -13 were 
significantly upregulated in co-cultured MΦ, with the strongest induction of MMP-13 
expression (Figure 22B-D). 
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Figure 22 VEGF expression LLC1 and MMP expression in macrophages. (A) Relative mRNA level of 
VEGFa-c in control (white bars) or co-cultured LLC1 (B) relative mRNA-expression levels of gelatinases (C) 
stromelysins and (D) collagenases in control and co-cultured MΦ. All data represent mean ± SEM, n = 6, 
*p≤0.05, **p≤0.01, *** p≤0.001. 
4.3 Functional characterization of co-culture CM 
4.3.1 Effect on LLC1 proliferation 
After observing upregulation of chemokine receptors CCR2 and CX3CR1, usually expressed 
on immune cells, LLC1 were examined by several functional assays, e.g. to investigate 
functional alterations in proliferation of LLC1 from co-culture with MΦ (Figure 23A-B). 
Proliferation, measured by BrdU-incorporation, was slightly but significantly increased in 
LLC1 exposed to CM from 12 h co-cultures. An even higher significance was seen in LLC1 
cultured with CM from 24 h co-cultures. Notably, the LLC1 proliferation was increased after 
treatment with CM from MΦ alone, which is in line with the observation that M-CSF 
generated MΦ display a slight M2-phenotype compared to GM-CSF-generated MΦ (Figure 
23C). 
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Figure 23 Effect of CM on LLC1 proliferation. (A) Schematic of experimental procedure (B) Positive (+) and 
negative (-) control (C) Proliferation of LLC1 stimulated with the indicated co-culture CM harvested on the 
indicated co-culture time points All data represent mean ± SEM, n = 6, *p≤0.05, **p≤0.01, *** p≤0.001. * 
compares LLC1 vs. co-culture, # compares LLC1 vs. MΦ. 
4.3.2 Effect on LLC1 migration 
After the moderate effect on LLC1 proliferation, LLC1 were examined using a boyden-
chamber-based migration assay (Figure 24A). The migration of LLC1 towards CM of MΦ 
alone was already increased 9 fold, suggesting that MΦ secrete either chemotactic working 
peptides or other soluble factors, which are able to prime cancer cells directly into a more 
metastatic phenotype. However, the migration toward co-culture CM was remarkably high at 
20 fold. Overall, the migration significantly increased after 12 h and 24 h towards CM from 
MΦ alone, as well as from co-cultures (Figure 24B-C). 
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Figure 24 Effect of CM on LLC1 migration. (A) Schematic of experimental procedure (B) Migration of LLC1 
stimulated with the indicated co-culture CM harvested on the indicated co-culture time points (C)  
Representative pictures of migrated LLC1 (D) Positive (+) and negative (-) control. All data represent mean ± 
SEM, n = 4, *p≤0.05, **p≤0.01, *** p≤0.001. * compares LLC1 vs. co-culture, § compares LLC1 vs. MΦ 
 
4.4 Knockdown of CCR2 and CX3CR1 in LLC1 
4.4.1 Effect on CCR2 and CX3CR1 expression  
To evaluate, if the observed CCR2 and CX3CR1 upregulation has any functional 
consequences for cancer cells, LLC1 were transduced with empty vector (EV), scramble 
shRNA (SCR) or shRNA against murine CCR2 or CX3CR1. Additional controls were 
performed with untransfected cells (UT). Transduced LLC1 were stimulated with either CM 
from LLC1 alone or co-culture CM, and screened for CCR2 (Figure 25A) and CX3CR1 
expression (Figure 25B). Stimulation with co-culture CM was necessary, since CCR2 is not 
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basally expressed in LLC1. Analysis of mRNA expression confirmed successful knockdown 
of CCR2 in shCCR2 transduced cells, and no effects in UT, EV, SCR or shCX3CR1 
transduced cells. shCX3CR1 transduced cells did not express CX3CR1 and the upregulation 
was abolished as well.  
 
Figure 25 Knockdown of CCR2 and CX3CR1 in LLC1. (A) relative mRNA-expression of CCR2 and (B) 
CX3CR1 after shRNA-mediated KnockDown All data represent mean ± SEM, n = 3, *p≤0.05, **p≤0.01,       
*** p≤0.001. 
4.4.2 Effect on LLC1 proliferation and migration 
Transduced LLC1 were then examined using proliferation (Figure 26A) and migration assays 
(Figure 26B) to analyze the functional consequences of CCR2 and CX3CR1 upregulation, 
respectively, on cancer cells. LLC1 were stimulated with CM from either LLC1 or MΦ alone 
or co-culture. The transduction itself had no effect on LLC1-proliferation. The MΦ CM and 
co-culture CM induced proliferation was partially, but significantly prevented in shCCR2-
transduced cells. The knockdown of CX3CR1 had no influence on proliferation. However, the 
effects on the migratory response to CM were notable. Interestingly, the migration of 
shCCR2-transduced cells was already significantly impaired towards MΦ CM. Migration of 
LLC1 with either CCR2- or CX3CR1-knockdown towards co-culture CM was reduced to less 
than 30% of any of the controls.  
In summary, if the MΦ-induced chemokine receptor upregulation is inhibited with CCR2 or 
CX3CR1 shRNA, LLC1 lose their ability to response to CM from MΦ and co-cultures, which 
is an important hint to a functional relevance of the co-culture-induced CCR2 and CX3CR1 
upregulation on cancer cells. 
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Figure 26 Knockdown of CCR2 impairs LLC1-proliferation and migration. (A) Proliferation and (B) 
Migration of LLC1 after shRNA-mediated Knockdown of CCR2 or CX3CR1 in response to indicated co-
culture- or control CM (harvested at 24 h) All data represent mean ± SEM, n = 3, *p≤0.05, **p≤0.01,               
*** p≤0.001. 
4.5 In vitro co-culture of bone-marrow derived CCR2-/- or CX3CR1-/- MΦ 
with LLC1 
4.5.1 Characterization of CCR2-/- and CX3CR1-/- MΦ 
Altogether these observations imply a crucial involvement of the CCR2-CCL2 and CX3CR1 
axis in lung cancer progression, and raised question as to whether the CCR2 and CX3CR1 
receptors have only unipolar involvement in lung cancer cell proliferation and migration or if 
they also play a role in their original host, MΦ. For this purpose, MΦ were isolated and 
generated from CCR2-/- or CX3CR1-/- mice and co-cultured with LLC1 as described above. 
The expression of the classical MΦ-marker F4/80, CD11b, MoMa1 and CD68 were compared 
to the WT MΦ using ICC. Overall, no difference in quantity or quality of the knockout MΦ 
was detected (Figure 27). 
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Figure 27 CCR2-/- and CX3CR1-/- macrophages. Immunocytochemistry for MΦ-marker  CD11b, CD68, F4/80 
and MoMa1 (from left to right)  
4.5.2 Effect on MΦ polarization 
Since MΦ adopt a very potent M2-phenotype after co-culture with LLC1, CCR2-/- MΦ and 
CX3CR1-/- MΦ were screened for polarization after co-culture with LLC1 as well. 
Surprisingly, CCR2-/- and CX3CR1-/- control MΦ already displayed a more M1-like 
phenotype as compared to WT MΦ simply due to the according knockout, with significantly 
lower expression of arginase and IL-10 and a significantly higher expression of IL-1β in 
CCR2-/- MΦ compared to WT MΦ. CX3CR1-/- MΦ showed a comparable expression pattern 
as WT MΦ, but with a significantly higher expression of the M1-marker IL-1β and the M2-
marker IL-1RA.  
Interestingly, the CCR2 knockout in MΦ significantly prevented co-culture induced MΦ-
polarization and the upregulation of all M2-markers was inhibited. Conversely, the 
downregulation of M1-marker iNOS and TNFα was not prevented. A similar effect was 
observed in CX3CR1-/- MΦ. The upregulation of M2-marker arginase, chitinase, IL-10 and 
IL1-RA was significantly abolished, whereas the downregulation of M1-markers iNOS and 
TNFα was not changed (Figure 28A-B). In conclusion, CCR2-/- and CX3CR1-/- MΦ are more 
resistant to cancer cell-induced M2-polarization and might function in restricting lung cancer 
cell growth and migration.  
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Figure 28 Effect of CCR2- and CX3CR1-knockout on macrophage polarization. (A) Relative mRNA levels 
of M2-marker arginase, chitinase, IL-10 and IL-1RA (B) M1-marker iNOS, IL-1β, IL-6 and TNFα and in WT 
(white bars), CCR2-/- (red bars) and CX3CR1-/- (purple bars) MΦ before and after co-culture. All data represent 
mean ± SEM, n = 3, *p≤0.05, **p≤0.01, *** p≤0.001, * WT Control vs. WT Co-culture,  WT vs. CCR2 -/- ,§ 
WT vs. CX3CR1-/-. 
4.5.3 Effect on CCR2 and CX3CR1 expression on LLC1 
After co-culture of LLC1 with either CCR2-/- or CX3CR1-/- MΦ, LLC1 were isolated and 
screened for relative mRNA expression levels of CCR2, CCL2, CX3CR1 and CX3CL1.  
Interestingly, the expression of CCR2 in LLC1 was no longer detected after co-culture with 
CCR2-/- MΦ, indicating that the expression of CCR2 is obligatory for the interplay with 
LLC1. In contrast, the expression of the ligand CCL2 was even higher than compared to WT-
co-culture, to compensate for the loss of CCR2 (Figure 29A-B). Surprisingly, the induction of 
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CX3CR1 expression by co-culture was significantly decreased after CCR2-/- co-culture, 
whereas higher levels of the ligand CX3CL1 were expressed (Figure 29C-D). 
As seen after CCR2-/- co-culture, the upregulation of CX3CR1 was reduced after CX3CR1-/- 
co-culture, though not completely abolished. In contrast, the upregulation of the ligand 
CX3CL1 was highly impaired after CX3CR1-/- co-culture compared to WT co-culture (Figure 
29C-D).  
 
 
Figure 29 CCR2 and CX3CR1 expression on LLC1 after co-culture with CCR2-/- and CX3CR1-/- MΦ. (A) 
Relative mRNA-expression levels of CCR2, (B) CLL2, (C) CX3CR1 and (D) CX3CL1 on LLC1 after 
stimulation with indicated CM derived from co-cultures of CCR2-/- or CX3CR1-/- MΦ. All data represent mean ± 
SEM, n = 3, *p≤0.05, **p≤0.01, *** p≤0.001. * WT Control vs. WT Co-culture,  WT vs. CCR2 -/- ,§ WT vs. 
CX3CR1-/-. 
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Interestingly, as observed after CCR2-/- co-culture, the induced upregulation of the second 
receptor CCR2 was significantly diminished, in CX3CR1-/- co-cultures (Figure 29C-D). 
These observations suggest a synergistic interaction between CCR2 and CX3CR1. 
4.5.4 Effect on LLC1 proliferation 
Proliferation of LLC1 subjected to CM derived from co-culture with either CCR2-/- or 
CX3CR1-/- MΦ was significantly reduced after CCR2-/- MΦ and CCR2-/- co-culture CM, 
though not strongly. Contrary to the observations in the CCR2 knockout, the proliferation of 
LLC1 after exposure to CX3CR1-/- CM was strongly impaired, with the maximum inhibited 
proliferation after co-culture CM of 24 h (Figure 30).  
Figure 30 Effect of MΦ-CCR2-/- or MΦ-CX3CR1-/- co-culture CM on LLC1 proliferation. All data represent 
mean ± SEM, n = 3, *p≤0.05, **p≤0.01, *** p≤0.001. * WT Control vs. WT Co-culture,  WT vs. CCR2-/- 
,§ WT vs. CX3CR1-/-. 
4.5.5 Effect on LLC1 migration 
Surprisingly, LLC1 migration was significantly abolished after treatment with CCR2-/- CM 
compared with WT CM. In particular, the migratory response to CCR2-/- co-culture CM was 
markedly decreased. The migration of LLC1 after exposure to CX3CR1-/- CM was not 
impaired after 12 h in both conditions (Figure 31A). After 24 h the migration of LLC1 
subjected to CX3CR1-/- MΦ-CM and CX3CR1-/- co-culture CM was significantly inhibited, 
although not as dramatically as exposure to CCR2-/- CM. (Figure 31B-C).   
Taken together, these results show a substantial impact of MΦ on lung cancer cells in 
enhancing their proliferation and migration as well changing the basal expression profile of 
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chemokine receptors. The effects of MΦ on LLC1 are significantly mediated via the CCR2-
CCL2 and CX3CR1-CX3CL1 axis. 
 
Figure 31 Effect of MΦ CCR2-/- or MΦ-CX3CR1-/- co-culture CM on LLC1 migration. (A) LLC1 migration 
towards CM as indicated after 12 h and (B) 24 h (C) Representative pictures of migrated LLC1. CCR2-/- and 
CX3CR1-/- are indicating the genotype of co-cultured MΦ. All data represent mean ± SEM, n = 3, *p≤0.05, 
**p≤0.01, *** p≤0.001, * WT vs. control, § WT vs. CCR2-/-,  WT vs. CX3CR1-/-. 
4.5.6 Effect on MMP and VEGF expression on MΦ 
The CCR2- or CX3CR1-knockout in co-cultured MΦ not only affected the LLC1, but also 
influenced the MMP expression in MΦ. After co-culture with CCR2-/- as well as CX3CR1-/- 
MΦ the upregulation of the in ovarian and neck cancer progression involved collagenase 
MMP-8 (Moilanen et al., 2002; Stadlmann et al., 2003) as seen after co-culture with WT MΦ 
was inhibited, although the upregulation of other MMPs was not influenced. Furthermore, 
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MMP-8 promotes infiltration of polymorphonuclear cells (Khatwa et al., 2010), which exerts 
a direct influence on the tumor microenvironment composition. 
 
Figure 32 MMP mRNA expression of control or co-cultured MΦ-CCR2-/- or MΦ-CX3CR1-/-. All data 
represent mean ± SEM, n = 3, *p≤0.05, **p≤0.01, *** p≤0.001, * WT vs. control, § WT vs. CCR2-/-,  WT vs. 
CX3CR1-/-. 
4.6 Primary tumor growth and metastasis in CCR2-/- and CX3CR1-/- mice 
4.6.1 Primary tumor growth 
To confirm the important role of CCL2 and CX3CL1 in cancer growth, LLC1 were injected 
s.c. in control and WT mice. After confirmation of tumor growth for 21 days, mice were 
sacrificed and plasma levels of CCL2 and CX3CL were evaluated using ELISA. As expected, 
CCL2 and CX3CL1 plasma levels were significantly elevated in tumor bearing mice. This 
data implies CCL2 and CX3CL1 are released in the blood circulation and are able to 
administrate systemic effects (Figure 33A-B).  
To further translate the in vitro observations to a living organism, LLC1 were injected s.c. in 
CCR2-/- and CX3CR1-/- mice and primary tumor growth was monitored over 21 days (Figure 
34A). As expected, the primary tumor growth was significantly reduced after day 16, with 
51% reduction of the final tumor volume and 59% reduction of the tumor weight in CCR2-/- 
mice compared to WT tumors (Figure 34 ). The measurements with digital calipers were 
confirmed with µCT scans (Figure 34 ). The tumor size in CX3CR1-/- mice was markedly 
reduced compared to the primary tumor growth in CCR2-/- mice, with a decrease of 65% in 
tumor volume and 60% in tumor weight in CX3CR1-/- compared to WT tumors. These results 
were confirmed by µCT scans. Notably, µCT pictures of whole resected tumors show a lack 
of surface vessels (Figure 34B-D). Both knockout-mice  show a better weight gain by trend    
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Figure 33 CCL2 and CX3CL1 plasma level in tumor bearing mice. (A) Plasma levels of CCL2 and (B) 
CX3CL1 in lung cancer syngraft models as estimated with ELISA. All data represent mean ± SEM, n = 6, 
*p≤0.05, **p≤0.01, *** p≤0.001. 
 
Figure 34 Primary tumor growths in CCR2-/- and CX3CR1-/- mice. (A) Schematic of experimental procedure 
(B) Representative pictures of resected tumors (C) Volume as measured with digital calipers at indicated time 
points (D) Tumor weight of extracted tumors (E) Tumor Volume as assessed with µCT (F) Bodyweight. All data 
represent mean ± SEM, n = 15, *p≤0.05, **p≤0.01, *** p≤0.001 * WT vs. CCR2-/- ,§ WT vs. CX3CR1-/-. 
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than WT mice. However, this effect might be due to the strongly decreased tumor size and 
does not necessarily reflect a better health condition of the mice (Figure 34E).  
Immunohistochemical analysis of primary tumor sections showed a significant decrease of 
PCNA+ tumor cells in CCR2-/- and CX3CR1-/- derived tumors, supporting the observed effects 
on primary tumor volume and weight (Figure 35A-B).  To further examine the correlation of 
infiltrated MΦ with primary tumor growth, accumulated TAMs in the tissue were stained with 
F4/80 in primary tumor sections. Quantification of MΦ by flow cytometry detected a highly 
significant reduction of 61% less MΦ in CCR2-/- tumors. Surprisingly, MΦ accumulation in 
the tumor environment of CX3CR1-/- only decreased by 44%, and was not as marked as in 
CCR2-/- mice, although the reduction was still very significant (Figure 35C-D). 
 
Figure 35 CCR2-/- and CX3CR1-/- displays less PCNA+ cells and macrophages in the tumor 
microenvironment. (A) Immunohistochemistry for PCNA and (B) Quantification (C) Immunohistochemistry 
for F4/80+ cells (D) Flow cytometric analysis of Macrophage-accumulation in s.c. tumor tissue. White arrows 
indicate positive cells. Data represent mean ± SEM, n = 6-10, * p≤0.05, ** p≤0.01, *** p≤0.001. 001 * WT vs. 
CCR2-/- ,§ WT vs. CX3CR1-/-. 
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Interestingly, the MΦ marker profile of tumors of CCR2-/- mice suggests lower amounts of 
M2-MΦ in the tumor compared to WT, as the mRNA levels of M2 markers arginase and 
chitinase are significantly decreased. No changes were detected in the M1 marker iNOS. The 
MΦ marker profile in CX3CR1-/-mice derived tumors was not shifted to M2 markers, as seen 
in the CCR2-/- tumor tissue, in which none of the MΦ markers were expressed (Figure 36A).  
Furthermore, the chemokine receptor CX3CR1 was strongly decreased in CCR2-/- tumors, 
whereas the mRNA expression of CCR2 was no longer detected.  
These results confirm in vivo that LLC1 require contact with CCR2 expressing MΦ to gain 
CCR2 expression. CX3CR1 was significantly down regulated in CX3CR1-/- tumors, while 
CCR2 expression was not changed (Figure 36B).  
Taken together, these observations in the CCR2-/- and CX3CR1-/-  model provide clear 
evidence, that cancer cells gain CCR2 expression, since the number of the main CCR2 
expressing cell population, MΦ, is significantly reduced in the CX3CR1-/- tumors, but CCR2 
expression in the tumor microenvironment did not changed. The same observation is true for 
CX3CR1, since CX3CR1 is detected at the mRNA level in CX3CR1-/- tumors, the only 
CX3CR1-expressing population can be the LLC1.  
To investigate further consequences of impaired MΦ trafficking on the tumor 
microenvironment, the tumor tissue was screened for VEGF and MMP expression on mRNA 
level. VEGFs are important for neoangiogenesis and neolymphangiogenesis, two processes 
that build the foundation for tumor progression and metastasis to distant organs. In CCR2-/- 
tumors, mRNA expression of VEGFa and VEGFb was significantly decreased, whereas 
VEGFc levels did not change. None of the VEGF levels were affected in the CX3CR1-/- 
tumor microenvironment (Figure 36C).  
Screening for MMP expression revealed a significant decrease of MMP-2, MMP-3, MMP-8 
and MMP-10 expression in tumors derived from CCR2-/- mice. In contrast, only MMP-2 and 
MMP-3 showed reduced expression in CX3CR1-/- tumor tissue compared to WT. Conversely, 
MMP-9 was upregulated in the CX3CR1-/- tumor microenvironment (Figure 36D-F). To 
unravel a possible mechanism of MΦ action on tumor growth, contrast fluid filled tumors 
were scanned with µCT and nanoCT to visualize the vascularization. The primary interest was 
if the total vessel volume in relation to the total volume was impaired in the knockout 
animals, compared with vessel volume/total volume ratios of the WT tumors.  The 
macroscopic vasculature evaluated with µCT, showed a trend of alteration in CCR2-/- mice,  
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Figure 36 mRNA expression profile in tumors derived from CCR2-/- and CX3CR1-/- mice reflects a less 
invasive tumor microenvironment. (A) Relative mRNA expression levels of MΦ-polarization marker (B) 
Chemokine receptors (C) VEGFs (D) Gelatinases (E) Stromelysins and (F) Collagenases. All data represent 
mean ± SEM, n = 6, *p≤0.05, **p≤0.01, *** p≤0.001. 001 * WT Control vs. CCR2-/- ,§ WT vs. CX3CR1-/-. 
but changes were significant in CX3CR1-/- mice, in which the vessel network was overall 
poorly developed (Figure 37A-B). A far more drastic effect was found after analysis with the 
nanoCT. The microvessel supply, given as a ratio of the total vessel volume/total volume, was 
massively decreased in CCR2-/- and CX3CR1-/- derived tumors, compared to WT-derived 
tumors (Figure 37A-C). This resulted in a broader vessel distribution, as represented by the  
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Figure 37 Vascularization in CCR2-/- and CX3CR-/-mice derived tumors  
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Figure 38 Vascularization in CCR2-/- and CX3CR-/-mice derived tumors:  
 (A) 3D-reconstructions of the vessel network in WT, CCR2-/- and CX3CR1-/- derived tumors. Upper panel: 
µCT-scans, representing macrovasculature, lower panel: nanoCT, representing microvasculature (B) Total vessel 
volume as assessed with µCT and (C) nanoCT (D) structure linear density, represents vessel distribution within 
the tumor (E) Vessel fractions according to their size. All data represent mean ± SEM, n = 3-8, *p≤0.05, 
**p≤0.01, *** p≤0.001, * WT vs. CCR2-/-; § WT vs. CX3CR1-/-. 
parameter “structure linear density”, which leads to a higher probability of inadequately 
supplied tumor areas, which in turn leads to an inhibited tumor growth (Figure 37D). In line 
with the findings described above in the CL-depleted model, mainly the vessels of sizes of 
0.017-0.039 mm2 are significantly decreased in the microenvironment of CCR2-/- mice and 
vessels of sizes of 0.017-0.050 mm2 in the CX3CR1-/- tumors, suggesting that MΦ have 
mainly  impact on the nurturing microvasculature (Figure 37E).  
Altogether, these results show a clear involvement of MΦ in tumor growth. Remarkably, the 
interruption of chemotactic pathways such as CCR2 and CX3CR1 results in an effect 
comparable to the complete systematic depletion of MΦ. Given that CCR2 and CX3CR1 can 
serve as potential new drug targets for lung cancer, this knowledge is very criticle, as a 
systemic depletion of MΦ in patients is not practicable.  
4.6.2 Lung metastasis formation in CCR2-/- and CX3CR1-/- mice 
The massive effect of CCR2 or CX3CR1 knockout on tumor vessel supply suggests a similar 
effect on metastasis formation, since intravasation of cancer cells into the tumor supplying 
vasculature is one of the initial steps of distant metastasis. To investigate the effects of   
CCR2-/- or CX3CR1-/- on lung metastasis, the tumor relapse model was used after s.c. LLC1 
injection in the according knockout mice (Figure 39A). In both knockouts, lung metastasis 
derived from the primary s.c. tumor was significantly decreased. This was reflected in the 
number of macroscopic, peripheral nodules on the lung surface, as well as the total metastasis 
as analyzed in H&E stained sections. The vessel structure in metastatic nodules appeared 
worse compared to healthy tissue as visualized with µCT. A similar worse vessel structure 
was already observed in the according primary tumors, thus these results again confirm the 
influence of CCR2-/- and CX3CR1-/- on the tumor vessel supply (Figure 39B-D). The reduced 
metastasis leads to a significantly better survival of the CCR2-/- and CX3CR1-/- mice 
compared to WT mice. The median survival for WT mice was 22 ± 1.3 days, compared to  
CCR2-/-  with 29 ± 2.6 days and CX3CR1-/- mice with 33 ± 0.88 days (Figure 39E). 
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Figure 39 Impaired lung metastasis formation in CCR2-/- and CX3CR1-/- mice.  
(A) Schematic of the experimental procedure (B) Representative picture of extracted lungs, H&E stained lung 
sections, MRI assessed lungs and 3D-reconstructions from µCT-scanned lungs (from up to down) (C) Number of 
macroscopic nodules found on the lung surface (D) Microscopic and Macroscopic nodules detected in H&E 
stained lung sections (E) Survival of CCR2-/-, CX3CR1-/- and WT mice. All data represent mean ± SEM, n = 3-8, 
*p≤0.05, **p≤0.01, *** p≤0.001, * WT vs. CCR2-/-; § WT vs. CX3CR1-/-. 
To evaluate the connection between lung metastasis formation and MΦ accumulation, MΦ 
were quantified in healthy lungs, and tumor sections from WT, CCR2-/- or CX3CR1-/- lungs. 
MΦ infiltration is represented as the ratio of F4/80+ to total cells, and the ratio was 
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significantly less in metastatic lung nodules in CCR2-/- and CX3CR1-/- lungs. Notably, the 
MΦ accumulation in CCR2-/- was again more marked in CX3CR1-/- mice, although overall 
not as strong as in the primary tumor model, due to already existing resident alveolar MΦ 
(Figure 40A-B). 
 
 
Figure 40 MΦ accumulation in metastatic lung nodules. (A) Immunohistochemistry for F4/80 in metastatic 
nodules in lungs derived from the indicated genotype and (B) Quantification. All data represent mean ± SEM, n 
≥ 8, *p≤0.05, **p≤0.01, *** p≤0.001, * Healthy vs. WT, § WT vs. CCR2-/- or CX3CR1-/-. 
4.7 CCR2 and CX3CR1 expression on human lung cancer cell lines and 
correlation with tumor stage and metastasis in human lung cancer patients 
4.7.1 CCL2 and CX3CL1 expression on human lung cancer cell lines 
To evaluate the relevance of CCR2/CX3CR1-upregulation for lung cancer in general, we 
screened 10 human lung cancer cell lines for CCR2-CCL2 and CX3CR1-CX3CL1 
expression. Importantly, CCR2 was not detected in any cell line, CX3CR1 was detected on 
very low levels (data not shown), whereas all cell lines expressed both ligands, CCL2 and 
CX3CL1 on different levels. This actuality supports the transferability of the observations 
made with mouse cell lines and models. Notably, squamous cell carcinomas (H520, H226) 
show overall the highest and large-cell lung cancers (H66a1, H460) the lowest CCL2-
expression (Figure 41A). No major differences of CX3CL1 expression were observed 
between histological lung cancer subtypes (Figure 41B). 
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Figure 41 CCL2 and CX3CL1 expression on human lung cancer cell lines. (A) relative mRNA levels of CCL2 
and (B) CX3CL1  
The four cell lines with the highest CCL2-expression (two adenocarcinomas: A549, H23; and 
two squamous cell carcinomas: H226, H520), were chosen for further experiments. All cell 
lines were co-cultured with human MC-derived MΦ and a substantial, co-culture-mediated 
induction of CCR2-expression was detected in all cell lines, with the overall strongest 
induction in A549.  Notably, mRNA-levels of CCL2 were significantly upregulated after co-
culture in all cell lines compared to control (Figure 42A and B). Though, CX3CR1-expression 
was significantly upregulated in H23 and H520 but not in H226 and A549. The according 
ligand  CX3CL1 was significantly upregulated in A549, H23 and H520 but not H226 (Figure 
42C and D). 
 These results confirm the importance of CCR2-CCL2 and CX3CR1-CX3CL1 axes for 
human lung cancer. 
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Figure 42 CCR2 onset and CX3CR1 upregulation after co-culture with MΦ. (A) Relative mRNA expression 
of CCR2, (B) CCL2, (C) CX3CR1 and (D) CX3CL1 on different human lung cancer cell lines. All data 
represent mean ± SEM, n = 3, *p≤0.05, **p≤0.01, *** p≤0.001. 
4.7.2 MΦ accumulation in tumor sections of lung cancer patients 
To assess the significance of our results for human lung cancer patients, 72 samples of human 
adenocarcinoma and squamous cell carcinoma sections were stained with CD68. Positive 
cells were counted and normalized to the total cell number. In adenocarcinoma and squamous 
cells carcinoma, the number of CD68+ cells strongly correlates with the tumor stage. As early 
as stage I carcinoma, more MΦ accumulated compared to healthy lungs. In contrast, there was 
no significant MΦ accumulation in the tumor tissue suggesting that MΦ seem to play a minor 
role in small cell lung cancer (Figure 43A-B). Importantly, the amount of CD68+ cells in the 
primary tumor also correlated with the metastastic stage, confirming the in vivo observations 
in the mouse models (Figure 43C).  
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Figure 43 Tumor infiltration of MΦ in lung cancer patients. (A) Immunohistochemistry for CD68+ cells in 
lung cancer sections with different state (B) MΦ-accumulation in relation to the lung cancer stage (C) and to the 
metastatic stage. All data represent mean ± SEM, n = 12, *p≤0.05, **p≤0.01, *** p≤0.001. 
4.7.3 MΦ become CCR2+ depending on lung cancer stage and metastatic status  
Furthermore, the accumulated MΦ in the tumor tissue become more CCR2+ in depending on 
the stage of adenocarcinoma and squamous cell carcinomas underlying the importance of this 
signaling pathway. Again this mechanism appears to play no role in SCLC (Figure 44A-B). 
Additionally, the MΦ in the primary tumor stroma become more CCR2+ in correlation with 
the metastatic stage (Figure 44C). Importantly, in advanced lung cancer stages, lung cancer 
cells also become CCR2+. Altogether these results show the importance and negative 
involvement of MΦ and CCR2+ cells in lung cancer development. 
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Figure 44 CCR2 expression on tumor infiltrating MΦ. (A) Immunohistochemistry for CCR2+ cells in lung 
cancer sections with different state (B) CCR2+ MΦ in relation to total MΦ in relation to the lung cancer stage (C) 
and to the metastatic stage. All data represent mean ± SEM, n = 12, *p≤0.05, **p≤0.01, *** p≤0.001. 
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5 Discussion 
5.1 MΦ depletion in primary tumor growth and metastasis 
This study reports an outstanding involvement of MΦ in lung cancer development and 
metastasis. A highly significant correlation between MΦ infiltration in areas with primary 
tumor growth and metastasis was demonstrated in two independent models of systemic MΦ 
depletion. These observed effects were associated with a changed microvasculature and a 
highly damaged vessel structure. Moreover, dramatic changes in the tumor 
microenvironmental expression patterns of MMPs, VEGFs and MΦ-markers were observed. 
MΦ have been reported to be one of the most prevalent cell types in the tumor 
microenvironment (Kelly et al., 1988). Their influence on cancer progression was previously 
demonstrated for several cancer types such as breast cancer, colon cancer, melanoma and 
urethane-induced cancer (Gazzaniga et al., 2007; Zaynagetdinov et al., 2011), but only little is 
known regarding their role in lung tumor formation. In the present study, the crucial role of 
MΦ in lung cancer development and metastasis was confirmed.  
The model of MΦ-depletion with CL-administration is well-established but is strongly 
dependent on the injection route. The chosen intraperitoneal application depletes 
phagocytosing MΦ derived from bone marrow, in the spleen, liver, some lymph nodes, in the 
peritoneal cavity and the circulation (van Rooijen et al., 1997; van Rooijen and van Kesteren-
Hendrikx, 2002). Since CL cannot cross intact vessel barriers, CL was additionally injected 
directly into the tumor to sustain a very successful MΦ depletion. However, in the tumor 
microenvironment, the expression of the typical M1-polarization marker iNOS was increased, 
indicating that the remaining MΦ are M1-MΦ with tumor-restrictive activity. Further, iNOS 
can be expressed by other cell types such as lymphocytes and vascular endothelial cells 
(Leifeld et al., 2002). To conclude, whether M1-phenotype MΦ are responsible for increased 
iNOS expression in the tumor microenvironment or other iNOS-expressing cells are elevated 
further analysis is required (e.g. IHC for F4/80 and iNOS double positive cells). A high 
expression of arginase-1 in MΦ is associated with an anti-inflammatory and angiogenetic 
activities and thus a tumor promoting M2-phenotype (De Palma et al., 2005; Pucci et al., 
2009). Another high arginase-expressing cell population are fibroblasts, in which arginase 
functions in collagen synthesis (Kitowska et al., 2008). Since fibroblasts are not affected by 
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CL-administration, the lower arginase expression in the tumor microenvironment might 
support the finding of a higher percentage of M1-MΦ of the remaining MΦ-population.  
In addition to the strong restriction of primary tumor growth in CL-depleted mice, a strong 
decrease of metastatic nodules in the lung was observed in the metastatic model. The reduced 
number of lung metastasis could be a secondary effect to the reduced primary tumor growth. 
Although the tumor size measured on day 10 (the day of primary tumor removal in the 
metastatic model) showed no difference between control and CL-treated groups, the tumor 
microenvironment of control mice could be already in a different state of activation compared 
to the CL-treated tumor microenvironment. In this context, the significant downregulation of 
several MMPs, as observed in the CL-depleted primary tumor model, may have contributed to 
the strongly impaired formation of metastatic nodules in the lung. In particular, expression of 
the stromelysins was impaired in primary tumors of CL-treated mice, an MMP subgroup that 
functions in the breakdown of basement membranes and extracellular matrix proteins, was 
impaired in primary tumors of CL-treated mice. MMP-3, -10 and -11 are strongly associated 
with metastasis (Delebecq et al., 2000; Gill et al., 2004; Justilien et al., 2012). Both MMP-9 
and MMP-13 were also downregulated, and MMP-13 is the only MMP that is known to be 
able to break down triple helical collagen structures, such as those found in cartilage and 
bones. Together with the fact that after the brain, bones are the second-most frequent site of 
metastasis for all lung cancer subtypes (Quint et al., 1996), this suggests a crucial role of 
MMP-13 in lung cancer progression and metastasis. Thus far, the role of MMP-13 was 
described in the development of breast-to-bone metastasis, and interestingly, the bone 
metastasis-promoting activity of MMP-13 involves the activation of MMP-9, which is 
significantly downregulated in CL-treated primary tumors as well (Morrison et al., 2011; 
Nannuru et al., 2010; Pivetta et al., 2011). 
Analysis of vessel supply and density revealed a remarkable decrease in macro- and 
microvasculature in CL-treated mice. The lack of a proper vessel supply, and thus adequate 
oxygen and nutrition, is important for primary tumor growth as well as for metastasis 
formation, since the intravasation of cancer cells in the systemic vasculature is the initiating 
step of metastatic spread. Angiogenesis is induced by members of the VEGF family (placental 
growth factor (PIGF), VEGFa-VEGFd), four members of the angiopoietin family (Ang1-
Ang4) and at least one member of the ephrin family (Ephrin B2). Further tumor 
neoangiogenesis can be induced by less-specific growth factors, such as PDGFβ, TNFα, IL-8 
and bFGF (Rehman and Jayson, 2005; Yancopoulos et al., 2000). Tumors of the CL-treated 
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mice exhibited significantly lower expression of VEGFc, which might be directly related to 
the decreased number of accumulated MΦ, since MΦ are a source for VEGFs and 
angiogenesis is triggered by a loop in which VEGF itself acts as a chemoattractant for 
monocytes, which in response secrete further VEGF. The correlation between VEGF 
expression in tumors and MΦ accumulation was previously demonstrated for breast cancer 
(Barleon et al., 1996; Grunewald et al., 2006; Leek et al., 2000). Moreover, VEGFc was 
shown to be important for lymph angiogenesis and importantly, like VEGFa, VEGFc binds to 
VEGFR-2 (Flk1, vascular endothelial growth factor receptor 2), which is the main receptor 
responsible for VEGF-mediated actions such as endothelial cell migration and angiogenesis. 
Furthermore, VEGFc was recently described to be the main angiogenetic factor in cancer. A 
properly developed microvessel density (MVD) promotes tumor progression and gives rise to 
metastatic spread (Carroll et al., 2013; Terme et al., 2013). However, other members of the 
VEGF family are not altered, so the screening should be extended to include the previously 
mentioned vascular growth factors. Furthermore, cancer cells secrete abundant levels of 
VEGF as well, which might adjust the lack of MΦ-secreted VEGF (Murdoch et al., 2004). 
It is known that tumor vessels can be leaky with heterogeneous flow profiles, since the 
stabilizing maturation phase is missing (Dewhirst, 1998; McDonald and Choyke, 2003). This 
effect on the vessel structure was even worse in the CL-depleted model. Nevertheless, in 
relation to tumor growth properties, the more drastic impact was the overall decrease of 
vessels in CL-depleted mice. Angiogenesis, which delivers optimal oxygen and nutrition 
supply, is required for tumors to grow beyond 500 µm in diameter. Heterogeneity in tumor 
perfusion results in hypoxia, an acidic microenvironment and a shift from an aerobic to an 
anaerobic metabolism of cells (Hanahan and Folkman, 1996; Vaupel et al., 1989). Hypoxia 
triggers cell apoptosis in a p53-dependent manner, and additionally HIF-1α was shown to 
mediate anti-proliferative and pro-apoptotic effects in embryonic stem cells (Carmeliet et al., 
1998; Graeber et al., 1996). In particular, the MVD could be correlated with prognosis in 
patients with solid tumors, such as head and neck, colorectal, breast and prostate cancers, and 
furthermore with the metastatic state of breast cancer (Cernea et al., 2004; Couvelard et al., 
2005; Fernandez-Aguilar et al., 2006; Lackner et al., 2004; Li et al., 2000; Lindmark et al., 
1996)  
A reduced number of accumulated MΦ was observed in both the MaFIA mice and CL-
depleted mouse models. Importantly, a significant shift of M2 to M1 polarization-marker was 
prominently observed only in tumor-bearing MaFIA mice. This shift might be influenced by 
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the model, since the suicide gene in MaFIA mice is driven by the cfms-promoter. The cfms 
gene encodes the M-CSF receptor CSFR1. Several in vitro studies demonstrated that MΦ-
polarization is dependent on GM-CSF vs. M-CSF-generation, whereas M-CSF stimulation 
facilitates the M2-phenotype (Fleetwood et al., 2009; Sierra-Filardi et al., 2010; Verreck et al., 
2004). Hence, in the MaFIA mice MΦ are preferentially depleted, although the process of 
MΦ-polarization is dynamic and reversible and not strictly dependent on only one stimulus. 
Nevertheless, these observations present the CSFR1 as a potential target for therapeutic 
intervention in lung cancer. Although the tumor size was decreased in both models compared 
to the control, the tumor-bearing MaFIA-mice benefitted more from the MΦ depletion as 
indicated by the gain of body weight over the time compared to controls. The CL-depleted 
tumor-bearing mice did not gain bodyweight. These observations indicate that the entire MΦ 
population has an impact on lung cancer growth, but that selective M2 MΦ-depletion in the 
MaFIA mouse model results in an enhanced improvement during the disease. These results 
confirm the importance of MΦ–polarization in lung cancer and emphasize the importance of 
M2-polarized tumor associated MΦ as a major promoter of tumor growth. 
In summary, the current study demonstrates and confirms that MΦ support lung cancer cell 
progression and metastasis formation, as reported previously for other cancer cell types such 
as colon and breast cancer. In addition, possible mechanisms underlying the changes in the 
tumor microenvironment induced by MΦ-cancer cell interactions, such as effects on the 
expression of several MMPs and VEGF, which could be associated with lung cancer 
progression, were  identified (Fakhoury et al., 2012; Zheng et al., 2010) 
5.2 LLC1-MΦ co-culture mediated effects on CCR2 and CX3CR1 
regulation and functional consequences 
To elucidate the underlying molecular mechanisms of MΦ action on lung cancer cells, we 
established an in vitro model for a lung cancer cell/MΦ co-culture. LLC1 were chosen to 
represent lung cancer cells. LLC1 are classified as adenocarcinoma, which is the most 
prevalent subtype of all lung cancers and the subtype with the lowest relationship to smoking 
(Chen et al., 2009; Kenfield et al., 2008). Both of these reasons support the use of 
adenocarcinoma in lung cancer research. Since human cancer cell lines require 
immunodeficient mice as a host in which cancer cell-host cell interactions might be 
influenced, using LLC1 with the syngeneic C57/Bl6 mice as a host remains the ideal model to 
study cancer cell-immune cell interactions within primary tumor growth and metastasis. 
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Nevertheless, it is crucial to show relevance to the human situation, so this study was not only 
extended to human cancer cell lines but also to other lung cancer subtypes, such as squamous 
cell carcinoma and large-cell carcinoma.  
 The co-culture was established without applying MΦ-like cell lines such as RAW264.7 or 
AMJ2 (Palleroni et al., 1991; Raschke et al., 1978) since these cell lines are immortalized by 
virus and/or oncogene transfection and thus exhibit cancer-like properties. The disadvantages 
of using primary cells are the more laborious and challenging culture as well as the need to 
apply the specific growth factors GM-CSF and M-CSF that already promote a pre-
polarization (Sierra-Filardi et al., 2010). Therefore, BM-MΦ were generated with M-CSF to 
mimic the M2-phenotype of TAMs. Nevertheless, M-CSF-generated MΦ displayed enough 
flexibility to respond to co-cultures with cancer cells adapting an even stronger M2-phenotype 
with high arginase, chitinase, IL-1RA and IL-10 expression.  
Interaction of cancer cells with MΦ lead to an increased proliferation and a potently increased 
migration of cancer cells, when stimulated with CM. MΦ are known to produce several 
growth factors such as TGF-β, epidermal growth factor (EGF) and PDGF (Lewis and Pollard, 
2006). A constitutive PDGF and EGF secretion of MΦ that was even increased after co-
culture was as well observed within this study (data not shown). The increased migration 
toward CM is most likely mediated via secreted cytokines. MΦ as well as cancer cells secrete 
abundantly chemokines such as CCL2, CCL5, CCL12, CXCL1, CX3CL1, MIP-1α and 
CXCL10, which mediate a chemotactic response of cells that express the according receptor. 
One possible mechanism would be the chemotactic response to CCL2 and CX3CL1, which 
are abundantly secreted in co-culture CM from MΦ- as well as cancer cells. The same CM 
induces an upregulation of CCR2 and CX3CR1 on cancer cells (see section below) that thus 
become able to respond to the CCL2- and CX3CL1-mediated chemotactic signal. However, 
only MΦ-CM induced already a migratory response of cancer cells but failed to induce 
chemokine-receptor upregulation, suggesting multiple mechanisms responsible for cancer cell 
migration in parallel to CCR2/CX3CR1-upregulation. Additionally to the cytokines and 
chemokines detected in this study MΦ as well as CAF are moreover able to secrete CXCL12 
(SDF-1, stromal cell-derived factor), whose involvement in cancer cell chemotaxis in vitro 
and metastasis in vivo could be demonstrated for several cancer types such as breast cancer, 
prostate cancer as well as NSCLC (Koshiba et al., 2000; Oonakahara et al., 2004; Orimo et 
al., 2005). Moreover, several inhibitors of the SDF-1/CXCR4 pathway, namely MDX-1338 
and plerixafor are currently in phase I/II or phase III trials (DiPersio et al., 2009; Kuhne et al., 
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2013), underlying the importance of chemotactic pathways for cancer progression and 
metastasis formation. Another chemotactic response of cancer cells could be demonstrated for 
CCL19/CCL21-CCR7 interactions in breast cancer and leukemia or upon CCL22 binding to 
CCR4 in lung cancer (Li et al., 2009; Muller et al., 2001; Picchio et al., 2008). Moreover, 
directed movement of cancer cells can take place in the presence of growth factors such as 
EGF, PDGF, FGF and IGF, which all can be secreted by MΦ. The migratory response of 
cancer cells towards growth factor was demonstrated for various cancer types including 
breast, lung, and pancreatic cancer as well as glioblastoma and melanoma (Roussos et al., 
2011). 
Interestingly, increased chemokine-receptor expression (CCR2 and CX3CR1) on LLC1 after 
co-culture with MΦ was observed. The upregulation was associated with enhanced 
proliferation and migration of LLC1. Importantly, the CCR2/CX3CR1 upregulation and the 
according functional consequences were strictly dependent on interaction with MΦ. 
Moreover, this effect was dependent on the expression of CCR2 or CX3CR1 in co-cultured 
MΦ. Suppression of CCR2 or CX3CR1 expression in either MΦ or LLC1 led to attenuated 
proliferation and migration.  
The present study is the first to report the upregulation of chemokine receptors on cancer cells 
in response to MΦ and the functional consequences from this upregulation. These findings 
imply that lung cancer cells can adapt to an expression and secretion profile that is similar to 
immune cells. Importantly, upregulations of CCR2 and CX3CR1 in LLC1 could enable 
possible response and migration towards chemotactic gradients of CCL2 and CX3CL1, which 
implies a crucial role in metastatic spread of lung cancer. The ligands CCL2 and CX3CL1 
were constitutively expressed by LLC1, yet significantly upregulated after MΦ co-culture. 
Abundant secretion of CCL2 by cancer cells was already previously reported for breast, 
prostate and pancreatic cancers, as well as gliomas (Brown et al., 2007; Monti et al., 2003; 
Qian et al., 2011; Zhang et al., 2010) and the major task is the recruitment of MΦ into the 
tumor microenvironment. Conversely, in pancreatic cancer, CCL2-mediated attraction of 
TAM was described as beneficial. However, the role of CX3CL1 in cancer progression has 
not been well investigated. Recent studies report the involvement of CX3CL1 in chemotaxis 
of TAM in breast cancer and lymphocytic leukaemia (Ferretti et al., 2011; Reed et al., 2012). 
Notably, CCR2 induction in LLC1 was connected to the MΦ-phenotype used for co-culture. 
This fact emphasizes the important role of CCR2 upregulation in cancer progression.  
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Importantly, the upregulation of CCR2/CCL2-axis was confirmed in several human lung 
cancer cell lines (A549, H23, H226, H520), emphasizing the relevance of this pathway for 
lung cancer in general. Furthermore, CX3CR1/CX3Cl1 axis was elevated in 50% of the used 
human cancer cell lines. Based on the fact that xenograft models with human cancer cells 
lines provide no information about metastatic behavior, it is difficult to elucidate the 
functional consequences  of CCR2/CX3CR1 upregulations on human cancer cells. However, 
the strong association of CCR2 with the tumor stage and metastatic stage could be confirmed. 
In line with the observed upregulation of CCR2 and CX3CR1 on cancer cells after co-culture 
with MΦ, is reversely the significantly lower expression of CCR2 and CX3CR1 in the tumor 
stroma of MΦ-depleted mice. This downregulation does partly reflect the MΦ-depletion itself, 
since CCR2 as well as CX3CR1 are abundantly expressed on MΦ. However, although other 
MΦ –marker are still well detectable, CCR2 is not detectable at all in the tumor stroma of 
MΦ-depleted mice, which suggest an outstanding role of CCR2+ subpopulations for cancer 
growth.  Recent publications demonstrated that CCR2+ MΦ-subpopulations are important for 
breast cancer metastasis, and siRNA-mediated knockdown of CCR2 in monocytes was shown 
to reduce tumor growth in mice models of lymphoma and colorectal cancer (Cortez-Retamozo 
et al., 2012; Leuschner et al., 2011; Qian et al., 2011). However, the role of CX3CR1+ cell 
populations in cancer growth and metastasis has not been investigated. 
The same group of genes (VEGFs, MMPs) as in the in vivo models was screened. In contrast 
to the decrease of VEGF in MΦ-depleted tumor stroma, a significant upregulation of VEGFa 
and VEGFc after LLC1/MΦ interaction was detected. This fact directly connects the observed 
microenvironmental changes in CL-depleted and MaFIA mice directly to MΦ-infiltration. 
The same tendency was reflected by upregulation of MMP-8, -9 and -13. The importance of 
MMP-9 and MMP-13, especially in invasiveness of solid tumors and metastasis, was 
previously described for various cancer types (Nannuru et al., 2010). However, the reported 
induction of MMPs in MΦ directly after interaction with lung cancer cells is novel. In contrast 
to the CL-depleted model in which MMP-8 was not decreased in primary tumors, it is 
upregulated after the LLC1/MΦ co-culture. MMP-8 was shown to correlate with the disease 
course in colorectal cancer and was directly associated with metastasis (Vayrynen et al., 
2012). Moreover, expression of proMMP as well as active MMP-8 was higher in breast 
cancer tissue compared to healthy controls (Kohrmann et al., 2009).  
That lung cancer cells and MΦ exhibit a strong interaction and exchange multiple secreted 
factors is evident. Yet the question remains as to how these interactions lead to upregulation 
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of the typical immune cell receptors CCR2 and CX3CR1 on cancer cells. Possible mediators 
of the MΦ-cancer cell interactions include the secreted cytokines, as several are either newly 
secreted or enhanced after co-culture. LLC1 abundantly secrete CCL2 and CX3CL1, but fail 
to autoregulate CCR2/CX3CR1 expression in response to their own CCL2/CX3CL1. 
Moreover, they fail to express CCR2/CX3CR1 in response to stimulation with MΦ-CM, 
although MΦ secrete CCL2/CX3CL1 as well. The missing piece to this puzzle might be one 
of the cytokines enhanced or newly secreted after co-culture, namely IL-1α, IL-6, IL-10, 
CCL1, IL-23, MIP-1α, MIP-1β, G-CSF, TNFα or siCAM-1. One possible candidate is IL-10, 
since it is upregulated in WT co-cultures, but not in MΦ-CCR2-/- co-cultures. Moreover, 
CCR2-/-MΦ display a more M1-like phenotype, and are less likely to secrete anti-
inflammatory cytokines such as IL-10. This is in line with the observation that CCR2 
upregulation on cancer cells is dependent on the phenotype of MΦ, with a stronger 
upregulation in response to M2-MΦ. CCR2/CCL2 was also highly upregulated in IL-10-
overexpressing mice compared to WT in the context of fibrosis (Sun et al., 2011). 
Furthermore, IL-10 was shown to upregulate CCR2-expression on human MC and thus 
increase their chemotactic response (Sozzani et al., 1998). Other cytokines, such as IL-6, were 
shown to upregulate CCL2-secretion, but had no influence on CCR2 expression (Arendt et al., 
2002). Thus far, no influence of CCL1, IL-23, MIP-1α on CCR2 expression has been 
described in the literature. Another candidate involved in co-culture-induced CCR2 
upregulation is G-CSF. G-CSF upregulated CCR2 transcription 86-fold after 8 hours of 
stimulation in the myeloid cell line FDN-1 (Iida et al., 2005). Whether the same effect would 
be observed in epithelial or cancer cells is not yet known. IL-2 is a well-known cytokine that 
enhances CCR2 expression on a transcriptional and translational expression level (Polentarutti 
et al., 1997). However, IL-2 was not secreted in either the control-CM or co-culture-derived 
CM, which is well in line with the fact that IL-2 is the major growth factor for T-lymphocytes 
but not for MΦ. Hence, these observations suggest an even higher CCR2-induction in vivo, 
with a well-established interplay among several cell types, such as cancer cells, MΦ and IL-2- 
secreting lymphocytes. Eventually, CCR2 expression on LLC1 is regulated by a distinct 
group of cytokines and the interaction and activation of several pathways finally leads to 
CCR2/CX3CR1 upregulation on cancer cells. A previous study demonstrated that an 
inflammatory pattern of cytokines, including IL-6, IL-1β and TNFα, causes CCR2 
downregulation to maintain recruited MΦ at the site of inflammation or disease and prevent 
reverse migration (Sica et al., 2000). In line with these observations, the CCR2-/- MΦ and 
CX3CR1-/- MΦ show an M1-phenotype with a pro-inflammatory cytokine profile.   
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The observation that several cytokines, instead of only one cytokine, show changes in 
expression implies that the CCR2/CX3CR1 is connected to a certain cytokine secretion 
profile of MΦ that mediates MΦ actions on cancer cells. Interestingly, both receptors seem to 
influence the expression of the other, as CX3CR1 expression had an effect on CCR2 
expression. CCR2 was downregulated in CX3CR1-/- MΦ. The exact molecular signaling 
patterns between MΦ and cancer cells that lead to upregulation of CCR2 and CX3CR1 
requires further investigation. 
5.3 In vivo influence of CCR2 and CX3CR1 on tumor growth and 
metastasis 
We uncovered a MΦ-dependent CCR2-CCL1 and CX3CR1-CX3CL1 upregulation in cancer 
cells in vitro. Furthermore, we demonstrated that the adapted expression of the chemokine-
receptors CCR2 and CX3CR1 on lung cancer cells is dependent on the expression of the 
receptors in MΦ. If MΦ lack CCR2 expression, they lose the ability to enhance cancer cell 
proliferation, migration and, most important, to induce CCR2 expression on cancer cells.  
Previous studies reported that hypoxia is mostly responsible for MΦ attraction to the tumor 
microenvironment (Murdoch et al., 2004). In this attempt an additional, excessive chemotactic 
attraction of MΦ to the tumor via CCL2 and CX3CL1 became evident. The systemic plasma 
levels of both cytokines were elevated during tumor progression in a grafted model. Once 
these axes are interrupted, tumor growth is impaired.  
Consistent with the in vitro data, CCR2-/- and CX3CR1-/- mice demonstrated decreased 
primary tumor growth, metastasis and improved survival compared to WT mice. Decreased 
primary tumor growth in CCR2-/- mice is well in line with previous reports in liver cancer and 
colon cancer (Wolf et al., 2012; Yang et al., 2006), whereas little is known regarding tumor 
growth in CX3CR1-/- mice. The decrease in tumor growth and metastasis correlated well with 
the MΦ infiltration and changes in the microvasculature in the tumor microenvironment. The 
impaired microvasculature might be a result of fewer accumulated MΦ in the tumor 
microenvironment. Moreover, CCR2+ MΦ in particular seem to be involved in angiogenesis, 
as shown in wound healing (Willenborg et al., 2012). Interestingly, the MΦ marker profile in 
tumor tissue derived from CCR2-/- was shifted to M1-phenotype markers, confirming the in 
vitro results of M1-polarization of CCR2-/--MΦ. Furthermore, CCR2 expression was not 
induced on cancer cells in vivo. In addition to the dramatically reduced metastasis in CCR2-/- 
mice, these results indirectly confirm our in vitro results showing that CCR2 expression is 
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connected to a distinct cytokine expression profile and/or MΦ phenotype, which induces 
CCR2 expression in cancer cells, and in turn primes these for metastasis.  
In contrast, the reduced tumor growth and metastasis in CX3CR1-/- mice were more likely 
caused by profound vessel changes not only in the microvasculature but also everywhere, 
implying that severe malnutrition is responsible for the impaired tumor growth and metastasis. 
Since CX3CR1 is not specifically expressed only on MΦ, but on all leukocyte subsets, other 
cell populations might be involved in the marked tumor impairment. Supporting this finding, 
CX3CL1- CX3CR1 was shown to induce endothelial cell dependent angiogenesis (Lee et al., 
2006).  
Despite these differences in the cause for impaired tumor growth in CCR2-/- or  CX3CR1-/- 
mice, overall the reduction in both mice is remarkable. This is to some extent surprising, since 
CCR2+ and CX3CR1+ MΦ are described as two different subpopulations. In the murine 
organism, within several MC-subpopulations, two either CCR2- or CX3CR1-expressing MC-
subtypes are described: (1) Ly6Chigh, CD11b+, CCR2high, CX3CR1low MC (MΦ-CCR2) and 
(2) Ly6Clow, CD11b+, CCR2low, CX3CR1high (MΦ-CX3CR1) (Palframan et al., 2001; Serbina 
et al., 2008; Shi and Pamer, 2011). Since CCR2 and CX3CR1 seem to be expressed on MC in 
a contrary way, one might expect different or even opposite functions of these different 
subpopulations. However, MΦ-CCR2 are  characterized as inflammatory MΦ, which 
accumulate abundantly upon infection with various bacteria, fungi, protozoa and viruses (Shi 
and Pamer, 2011). In contrast, decreased accumulation of MΦ-CCR2 was associated with a 
milder progression of influenza virus-provoked pneumonia, and thus with decreased mortality 
(Aldridge et al., 2009; Dawson et al., 2000). In the context of HIV, CCR2 could be associated 
with a response to anti-inflammatory cytokines (M2-phenotype) (Sozzani et al., 1998). This 
study could confirm this, since CCR2-/- MΦ displayed a more M1-like phenotype. This fact 
might once more support the finding of decreased tumor growth in CCR2-/-, since not just less 
MΦ are accumulated in the tumor microenvironment but additionally the remaining (resident) 
MΦ are tumor restrictive M1- MΦ.   
In contrast, the function of MΦ-CX3CR1 is much less investigated. These MC are described 
as vessel-patrolling MC. However, they also accumulate upon bacterial infection (Auffray et 
al., 2007; Auffray et al., 2009; Landsman et al., 2009). CX3CR1 expression was not 
associated with a certain MΦ-phenotype yet, and CX3CR1-/- MΦ could not be assigned to a 
phenotype in the current study. However, CX3CR1-signaling facilitates prolonged survival of 
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MC (Landsman et al., 2009), which might result in shorter life span and thus less operative 
time within the tumor microenvironment of CX3CR1-/- MΦ.   
Eventually, in various diseases the accumulation of both MΦ-CCR1 and MΦ-CX3CR1 could 
be described, and inhibition of the accumulation of one of them turned out beneficial, so that 
altogether both MΦ-subpopulations are not acting as differently as expected but rather 
synergistically. Moreover, transfer of the separation in MΦ-CCR2 and MΦ-CX3CR1 in the 
human organisms proves to be difficult. Based on functional similarity, MΦ-CCR2 in humans 
are CD14+, CD16- and CCR2+. Patrolling, MΦ-CX3CR1-similar MΦ are CD14+, CD16+ 
(Cros et al., 2010; Geissmann et al., 2003; Ziegler-Heitbrock, 2007). In consequence, CCR2 
or CX3CR1 expression cannot be strictly associated with a certain subpopulation, since the 
expression on MC in the human organism is not as exclusive as in the mouse. Importantly, in 
this study CCR2 and CX3CR1 expression and not only MΦ-accumulation, could be 
correlated with worse disease progression and metastasis. 
Summarized, our findings therefore suggest that CCL2-CCR2 and CX3CR1-CX3CL1 
chemokines represent potential anti-cancer therapies that bidirectionally target MΦ and cancer 
cells in the tumor microenvironment. Thus, blocking CCR2/CX3CR1 (1) targets cancer cells 
directly, reduces proliferation and impairs the migratory response to CCL2/CX3CL1 and (2) 
targets MΦ trafficking into the tumor microenvironment. 
5.4 Patient data 
To assess the human relevance of the described results, MΦ infiltration was estimated in 72 
lung tissue sections from cancer patients. The sections covered NSCLC, especially 
adenocarcinoma and squamous cell carcinoma, in different stages and with different 
metastatic lymph node involvement and SCLC sections. MΦ accumulation, as represented by 
CD68+ cells, strongly correlates with stage and metastatic stage. However, MΦ polarization 
was not considered in this study, but several published studies describe a M2-polarization for 
TAM. Moreover, correlation of MΦ-infiltration and stages in SCLC was not feasible, since 
SCLC is only classified in extensive or limited disease (Kalemkerian and Gadgeel, 2013; 
Micke et al., 2002), although attempts are made to extend the (for NSCLC usual) TNM 
staging system to SCLC. Overall, MΦ-accumulation seems to play a minor role in the 
progression of SCLC. This might be related to the neuroendocrine origin of SCLC and its 
abundant secretion of ectopically produced hormones such as adrenocorticotropic hormone 
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(ACTH) and anti-diuretic hormone (ADH), rather than  cytokines (Gandhi and Johnson, 2006; 
Pelosof and Gerber, 2010; Raftopoulos, 2007).  
Furthermore, evaluation of CD68+CCR2+ cells showed a correlation to tumor stage and 
metastatic spread as well. Notably, these immunohistochemical stainings identified CCR2+ 
tumor cells, especially in advanced stages. These observations need to be quantified with 
appropriate adenocarcinoma and squamous cell carcinoma markers. However, 
adenocarcinoma or squamous cell carcinoma markers are not completely specific; most lung 
cancer subtypes show heterogeneous expression profiles and some markers are also expressed 
on healthy epithelial cells (Molina et al., 2003; Tacha et al., 2012). This makes a 
quantification of CCR2+ tumor cells challenging. Interestingly, no CCR2+ cells were detected 
in healthy lungs. This approach needs to be extended to CX3CR1+ cells in correlation with the 
lung cancer stage. 
5.5 Conclusion 
Tumor cells and MΦ exhibit an extensive communication network via several secreted 
mediators and receptors within the tumor microenvironment. Based on the observed results, 
the following critical  steps for tumor progression and metastasis can be summarized: (1) 
Tumor cell-host cell interactions are not limited to the tumor microenvironment but include 
the systemic pool of immune cells such as MC. Tumor cells actively attract monocytes via 
CCL2 and CX3CL1 from the blood stream. Systemic plasma levels of CCL2 and CX3CL1 in 
tumor-bearing mice are constantly high. (2) After migration into the tumor stroma, MC 
differentiate and polarize into M2-MΦ in response to tumor-cell-secreted M-CSF (among 
other factors) (3) In return, MΦ-secreted-factors (e.g. IL-10, Il-1α, IL-1β, CCL5, CXCL10 
amongst others), in particular IL-10 might play a key role and induce CCR2 and CX3CR1 
expression in tumor cells. (4) Expression of CCR2 and CX3CR1 supports the proliferation 
and migration of the tumor cells. Simultaneously, MΦ and tumor cells secrete MMPs, VEGFs 
and growth factors (GF; PDGFa, PDGFb, EGF etc), which cause microenvironmental 
changes and promote tumor progression. (5) The enhanced migration of tumor cells finally 
results in metastasis formation.  
Several for crucial steps for tumor development can be blocked by knocking out CCR2 and 
CX3CR1 in MΦ, and thereby blocking connected signaling events such as IL-10 secretion 
and CCR2 and CX3CR1 up regulation in tumor cells.  
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Figure 45 Diagram of signaling events in the tumor microenvironment involving CCR2 and CX3CR.             
1) Tumor cells attract monocytes via CCL2 and CX3CL1 from the blood stream. 2) After migration into the 
tumor stroma, MΦ are differentiated and polarized into M2-MΦ via M-CSF (amongst others). 3). In return they 
secrete factors (e.g. IL-10) that induce CCR2 and CX3CR1 expression in tumor cells. 4). Expression of CCR2 
and CX3CR1 support the proliferation and migration of the tumor cells. Simultaneously MΦ and tumor cells 
secret MMPs, VEGF and growth factors (GF; PDGFa, PDGFb, EGF etc), which cause microenvironmental 
changes and promote tumor progression. 5). The enhanced migration of tumor cells finally results in metastasis 
formation. The described signaling loop can be attenuated by inhibition of CCR2/CX3CR1 signaling on either 
MΦ or cancer cells. 
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5.6 Outlook 
• Further investigations should focus on the underlying mechanisms of CCR2 and 
CX3CR1 regulation of cancer cells. IL-10 might be a key player in CCR2 and 
CX3CR1 regulation, but several other cytokines are newly or more abundantly 
secreted after co-culture, such as IL-6, IL-1α, IL-23, M-CSF, TNFα, IL-6, CCL1, 
MIP-1α, MIP-1β, G-CSF and soluble ICAM-1. Furthermore, initiation and termination 
of inflammatory reactions is frequently orchestrated by a distinct pattern or group of 
cytokines; therefore, overlapping and interacting pathways are expected. Additionally, 
the detection of cytokines with antibody arrays or RT-PCR is very limited, and thus 
signaling proteins such as enzymes, growth factors, further cytokines and chemokines 
involved in and regulated by cancer cell-MΦ co-cultures might not be yet detected in 
this study. The entire secretome of MΦ and cancer cells with or without co-culture 
could be determined with a proteomic approach. This approach could also be extended 
to the proteome of cancer cells/MΦ.  
• Other possibilities include investigations of the transcriptome with microarrays or 
miR-expression profiles in cancer cells/MΦ. The elucidation of dysregulated pathways 
specific to cancer cell-MΦ interactions opens up research to new and better targets for 
lung cancer treatment.  
• Additional studies should be performed to validate CCR2 and CX3CR1 as suitable 
targets for lung cancer intervention. In particular, treatment of tumor-bearing mice 
with CCR2/CX3CR1-blocking antibodies or chemical receptor antagonists is 
necessary to evaluate the pharmacological characteristics and possibilities of a 
xenobiotic intervention. A 100% receptor blockade as achieved with a genetic 
knockout is unlikely to achieve the general pharmakodynamic and  kinetic properties 
from xenobiotics.  
• Finally, CCR2 should be considered as a diagnostic marker for staging and metastatic 
states, since the expression in primary tumors correlated clearly with the primary 
tumor stage and metastasis. For this purpose, more extensive patient studies need to be 
performed.   
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6 Summary 
 
Recent studies indicate that tumor-associated macrophages with an M2 phenotype can play a 
critical role in tumor growth and metastasis. However, the regulatory pathways remain poorly 
characterized. Using macrophage (MΦ)-depleted mice, the present study confirms a major 
contribution of MΦ to primary lung cancer growth and metastatic spread. Furthermore, the 
data demonstrates that M2-polarized MΦ play a critical role in establishing the vessel 
structure and microvasculature associated with tumors. Depletion of MΦ restricts the 
expression of matrix metalloproteinases and vascular endothelial growth factor and thus 
results in an overall regressive tumor microenvironment. 
Co-culture experiments of MΦ with lung carcinoma cells revealed cancer-cell-mediated M2-
polarization and subsequent M2-MΦ-induced proliferation, migration and CCR2/CX3CR1 
expression on carcinoma cells. Importantly, adenocarcinoma cells initiate a vicious circle with 
an abundant secretion of tumor-associated MΦ-attracting CCL2/CX3CL1, and then recruited 
MΦ polarize into M2, enhance CCL2/CX3CL1 secretion and induce CCR2/CX3CR1 
expression of cancer cells with the functional consequence of enhanced cancer cell 
proliferation and migration. The co-culture-induced cytokines interleukin-10, interleukin-6, 
interleukin-1α, and interleukin-23, CCL1, macrophage-colony stimulating factor, tumor 
necrosis factor α, macrophage inflammatory proteins 1α and 1β, granulocyte-colony 
stimulating factor and soluble intercellular adhesion molecule 1 may play a crucial role in this 
cycle. Inhibition of CCR2/CX3CR1 signaling on either lung cancer cells or MΦ attenuates co-
culture induced proliferation and migration. In conclusion, lung adenocarcinoma cells hijack 
CCR2/CX3CR1+ MΦ to support their own proliferation and migration. 
Consistent with these observations, both CX3CR1-/- and CCR2-/- mice had reduced primary 
tumor size, lung metastasis and numbers of M2-polarized MΦ compared to WT mice. With 
the absence of CCR2+ or CX3CR1+ MΦ, induction of CCR2/CX3CR1 on cancer cells also 
failed in vivo. These results support a model whereby TAMs play a critical, chemokine 
dependent role in the regulation of lung cancer progression. Furthermore, studies with 
CX3CR1-/- and CCR2-/- reveal a similar reduction of tumor-associated neoangiogenesis with 
in particular targeted microvasculature and moreover a similar restriction of matrix 
metalloproteinases and vascular endothelial growth factor expression compared to total MΦ-
depleted mice. Consequently, this study indicates CCR2 and CX3CR1 as promising drug 
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targets to inhibit cancer progression and metastasis by directly manipulating the tumor 
microenvironment. The enhanced concentration of CCR2 and CX3CR1 expression in the 
tumor microenvironment provides ideal conditions for this purpose.  
Finally, not only MΦ infiltration but also the ratio of CCR2+ MΦ within human lung 
adenocarcinoma and squamous cell carcinoma correlate with lung cancer stage and 
metastasis. These observations confirm the human relevance of TAM-associated 
CCR2/CX3CR1-signaling cascades.  
Altogether, these results provide a mechanism for the regulation of lung tumor growth and 
metastasis by tumor-associated macrophages, and targeting M2-macrophage expressed 
receptors provides a new strategy for the development of lung cancer therapeutics.  
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7 Zusammenfassung 
 
Neueste Studien belegen eine entscheidende Rolle von Tumor-assoziierten Makrophagen mit 
M2-Phenotyp innerhalb von Tumorentstehung, Fortschritt der Erkrankung und letzten Endes 
Metastasierung. Dennoch verbleiben dieser Beobachtung zugrunde liegende Signalwege und 
Regulationsmechanismen besonders in Bezug auf Lungenkarzinome weitestgehend 
unbekannt. Die vorliegende Studie bestätigt diese Schlüsselrolle der Makrophagen in 
Primärtumorwachstum der Lunge und Entstehung von peripheren Metastastasen, unter zu 
Hilfenahme zwei verschiedener Makrophagen-depletierter Maus-modelle. Im Weiteren wird 
nachgewiesen, dass M2-polarisierte Makrophagen eine tragende Rolle bei der Ausbildung von 
Tumor-assoziierten Gefäßstrukturen, insbesondere Mikro-zirkulation spielen. Die Depletion 
von Makrophagen führt weiterhin zu einer verringerten Expression von Matrix- 
Metalloproteinasen und vascular endothelial growth factor (VEGF) und damit zu einem 
insgesamt überwiegend Tumor-restriktiv agierenden Tumor-Stroma. 
Die durchgeführten Experimente mit in einer Co-Kultur befindlichen Makrophagen und 
Lungenkarzinom-Zellen offenbaren eine Krebszellen-vermittelte M2-Polarisation der 
Makrophagen mit nachfolgender M2-Makrophagen induzierter Proliferation, Migration und 
CCR2-/CX3CR1 Expression von/auf Krebszellen. Im Wesentlichen wird hierbei ein 
Teufelskreis ausgelöst, beginnend mit der mit der beträchtlichen CCL2/CX3CL1-Sekretion 
von Adenokarzinomzellen, um direkt Makrophagen in das Tumor-Stroma zu rekrutieren, die 
daraufhin einen M2-Phenotypen ausbilden um anschließend wiederum die CCL2/CX3CL1-
Sekretion zu verstärken und eine CCR2/CX3CR1-Expression auf Adenokarzinomzellen zu 
induzieren. Dies führt funktionelle Konsequenzen für die Krebszellen herbei, insbesondere 
eine verstärkte Proliferation und Migration. Weitere Schlüsselfunktionen in diesem 
Teufelskreis könnten dabei von Co-Kultur induzierten Zytokinen und Chemokinen wie 
Interleukin-10, -6, -1α, und -23, CCL1, macrophage-colony stimulating factor (M-CSF), 
tumor necrosis factor α (TNFα), macrophage inflammatory proteins-1α and -1β, granulocyte-
colony stimulating factor (G-CSF) und soluble intercellular adhesion molecule 1 (siCAM-1) 
übernommen werden. Wird die CCR2/CX3CR1-übermittelte Signaltransduktion nun auf 
Makrophagen oder Lungenkrebszellen inhibiert, werden folglich auch die durch Co-Kultur 
erzeugte gesteigerte Proliferationsrate sowie Migrationsverhalten stark abgeschwächt. Somit 
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missbrauchen Lungenadenokarzinomzellen im Speziellen CCR2/CX3CR1+ Makrophagen um 
ihre eigene Proliferation und Migration zu fördern. 
Im Einklang mit diesen Beobachtungen, wurden in CX3CR1-/- und CCR2-/--Mäusen ein 
reduziertes Primärtumorwachstum, eine geringere Anzahl an Lungenmetastasen sowie 
weniger M2-polarisierte Makrophagen im Vergleich mit WT-Mäusen festgestellt. Durch den 
Mangel an CCR2/CX3CR1+ Makrophagen, ist auch in vivo die Induktion von 
CCR2/CX3CR1-Expression auf Krebszellen fehlgeschlagen. Diese Ergebnisse unterstützen 
das Model von Tumor-assoziierten Makrophagen als ausschlaggebende, Chemokin-abhängige 
Regulatoren im Voranschreiten einer Lungenkrebserkrankung. Des Weiteren konnte in 
CX3CR1-/- und CCR2-/--Mäusen ein ähnlicher Einfluss auf die Neoangiogenese, mit 
besonders beeinträchtigter Mikrozirkulation, sowie eine gleichermaßen verringerte 
Expression/Sekretion von Matrix- Metalloproteinasen und vascular endothelial growth factor 
(VEGF) im Vergleich zu den Maus-Modellen mit totaler Depletion von Makrophagen 
beobachtet werden. Folglich konnten in dieser Studie CCR2 und CX3CR1 als 
vielversprechende  Zielrezeptoren für Medikamente präsentiert werden, mit deren Inhibition 
oder Blockade es möglich wäre, Lungenkrebs durch direkte Manipulation des Tumor-Stroma 
zu therapieren.  
Letztendlich korreliert nicht nur die gesamte Makrophagen-Infiltration, sondern auch der 
Prozentsatz an CCR2+ Makrophagen mit dem Schwere- und Metastasierungsgrad von 
pulmonalen Adenokarzinomen und Plattenepithelkarzinomen im Patienten. Damit konnte eine 
Relevanz für TAM-assoziierte CCR2- und CX3CR1-Signalkaskaden für den Patienten gezeigt 
werden.  
Zusammengefasst wird in dieser Arbeit ein möglicher Mechanismus für Makrophagen-
induziertes Primärtumorwachstum sowie Metastasen Bildung aufgezeigt, der Makrophagen-
exprimierte Rezeptoren und Moleküle als neue Targets für die Entwicklung neuer 
Therapieansätze für Lungenkrebs aufdeckt.  
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8 List of Abbreviations 
 
-/-   Knockout of indicated gene 
∆Ct   Threshold-cycle difference (HPRT-GOI) 
AC   Adenocarcinoma 
ALK   Anaplastic lymphoma kinase 
APC   Antigen presenting cell 
BAC   Bronchoalveolar carcinoma 
BM-MΦ  Bone marrow derived Macrophages 
BRaf   v-Raf murine sarcoma viral oncogene homolog B1 
Ca2+   double positive calcium ion 
CAF   Cancer associated fibroblast 
cAMP   Cyclic adenosine monophosphate  
CCL2/MCP-1  Chemokine (C-C motif)-Ligand 2/Monocyte chemotactic protein 1 
CCR2/CD192  Chemokine (C-C motif)-receptor 2  
CCR3/CD193  Chemokine (C-C motif)-receptor 3  
CD   Cluster of differentiation 
CEA   Carcinoembryonik antigen 
CK   Cytokeratin 
CL   Clodronate liposomes 
CM   Conditioned media 
CSFR1  Colony-stimulating factor receptor 1 
CT   Computed tomographie 
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CX3CL1/FKN Chemokine (C-X3-C motif)-ligand 2/Fractalkine 
CX3CR1  Chemokine (C-X3-C motif)-receptor 1 
CYFRA 21-1  Fragment of the cytokeratin 19 
DC   Dendritic cell 
DMSO  Dimethyl sulfoxide 
ECM   Extracellular matrix 
EGFR   Epidermal growth factor receptor 
ETS   Environmental tobacco smoke 
FAP   Fibroblast activation protein 
FCS   Fetal calf serum 
FGF   Fibroblast growth factor 
FSP-1   Fibroblast specific protein 1 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GOI    Gene of interest 
HER1   Human epidermal growth factor receptor 2 
HGF   Hepatocyte growth factor 
IA   Invasive adenocarcinoma 
IFNγ   Interferon γ 
IL   Interleukin 
IL-1RA  Interleukin 1 receptor antagonist 
iNOS   Inducible nitric oxide synthases 
JAK   Janus kinase 
KO   Knockout 
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KRas   V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LKB-1   Liver kinase B1  
LLC1   Lewis lung carcinoma 1 
LPS   Lipopolysaccharide 
MΦ   Macrophages 
MΦ -CCR2-/-  CCR2 knockout macrophage 
MΦ -CX3CR1-/- CX3CR1 knockout macrophage 
M1   Macrophage with M1-phenotype 
M2   Macrophage with M2-phenotype 
MaFIA  Macrophage FAS-induced apoptosis 
MAPK  Mitogen-activated protein kinase 
MC   Monocyte 
MC-CCR2  Ly6Chigh, CD11b+, CCR2high, CX3CR1low monocyte 
MC-CX3CR1  Ly6Clow, CD11b+, CCR2low, CX3CR1high monocyte 
M-CSF  Macrophage colony stimulating factor 
MET   Proto-oncogene encoding for hepatocyte growth factor receptor  
MHC-II  Major histocompatibility complex Class II 
MIA   Minimally invasive adenocarcinoma 
MMP   Matrix metalloproteinase 
MUC-1  Mucin 1 
MRI   Magnetic resonance imaging 
MVD   Microvessel density 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
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NK-Cells  Natural killer cells 
NSCLC  Non-small cell lung cancer 
NSE   Neuron specific enolase 
PBS   Phosphate buffered saline 
PIK3CA  Class I PI 3-kinase catalytic subunit 
PDGFR  Platelet-derived growth factor receptors 
proGRP   Gastrin-releasing peptid-progenitor 
SCC   Squamous cell carcinoma 
SCLC   Small cell lung cancer 
SMA   Smooth muscle actin 
Sox2   Sex determining region Y-box 2 
STAT   Signal transducers and activators of transcription 
TAM   Tumor associated macrophage 
TAN   Tumor associated neutrophil 
TGFβ   Transforming growth factor β 
TH   T-helper cell 
TTF-1   Thyroid transcription factor 
TKI   Tyrosine-kinase inhibitor 
TNFα   Tumor necrosis factor α 
TREG   Regulatory T-cell 
VEGF   Vascular endothelial growth factor 
WT   Wildtype
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11 Appendix 
 
Coordinate Target Alternate Nomenclature 
A1-2 Positive Control Control (+) 
A23-24 Positive Control Control (+) 
B1-2 BLC CXCL13/BCA-1 
B3-4 C5a Complement Component 5a 
B5-6 G-CSF  
B7-8 GM-CSF  
B9-10 I-309 CCl1/TCA-3 
B11-12 Eotaxin CCL11 
B13-14 siCAM-1 CD54 
B15-16 IFNγ  
B17-18 IL-1α IL-1F1 
B19-20 Il-1β IL-1F2 
B21-22 IL-1ra IL-1F3 
B23-24 IL-2  
C1-2 IL-3  
C3-4 IL-4  
C5-6 IL-5  
C7-8 IL-6  
C9-10 IL-7  
C11-12 IL-10  
C13-14 IL-13  
C15-16 IL-12 p70  
C17-18 IL-16  
C19-20 IL-17  
C21-22 IL-23  
C23-24 IL-27  
D1-2 IP-10 CXCL10/CRG-2 
Appendix 
 
 
 
139
D3-4 I-TAC CXCL11 
D5-6 KC  
D7-8 M-CSF 
 
D9-10 JE CCL2/MCP-1 
D11-12 MCP-5 CCL12 
D13-14 MIG CXCL9 
D15-16 MIP-1α CCL3 
D17-18 MIP-1β CCL4 
D19-20 MIP-2  
D21-22 RANTES CCL5 
D23-24 SDF-1 CXCL12 
E1-2 TARC CCL17 
E3-4 TIMP-1  
E5-6 TNFα TNFSF2 
E7-8 TREM-1  
F1-2 Positive Control Control (+) 
F23-24 PBS (Negative Control) Control (-) 
 
Table 17 Cytokine Array coordinate
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